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ABSTRACT	  Breast	  cancer	  stem	  cells	  (BCSCs)	  are	  defined	  as	  a	  minor	  cellular	  component	  in	  the	  solid	  tumor,	   displaying	  mammary	   stem	   cell	   properties	   by	   expressing	   embryonic	   stem	   cell	  genes.	  They	  are	  usually	  undergoing	  self-­‐renewal	  process,	  but	  highly	  potent	  to	  give	  rise	  to	  other	  types	  of	  tumor	  cells	  and	  create	  a	  hierarchically	  arranged	  tumor	  under	  certain	  stimuli.	  Accumulating	  evidences	  suggest	  that	  BCSCs	  are	  more	  resistant	  to	  conventional	  therapies	   and	   play	   an	   important	   role	   in	   mediating	   tumor	   metastasis	   and	   relapse.	  Therefore	   more	   targeted	   therapy	   on	   the	   scope	   of	   BCSCs	   is	   required	   to	   improve	  prognosis	  of	  breast	  cancer	  patients.	  	  
Two	  estrogen	  receptors	   (ER)	  exist	   in	  breast	  cancer:	  ERα	   and	  ERβ.	  Around	  75%	  of	  all	  primary	  breast	  tumors	  can	  be	  identified	  as	  ERα	  positive.	  In	  study	  I,	  we	  confirm	  BCSCs	  derived	   from	   human	   tumors	   as	   well	   as	   cell	   lines	   are	   absent	   of	   ERα	   expression	   but	  dominant	  in	  ERβ	  expression.	  We	  show	  that	  ERβ	   is	  correlating	  with	  phenotypic	  cancer	  stem	  cell	  markers	  and	   responsible	   for	   the	  proliferative	   role	  of	   estrogens	  and	   thereby	  essential	   for	   tumor	   growth.	  We	   also	   observe	   ERβ	   activated	   gene	   signature	   in	   BCSCs	  associated	  with	  poor	  outcome	   in	   three	   independent	  breast	   cancer	   cohorts.	  By	   in	   vivo	  xenograft	   experiments	   we	   show	   that	   agonizing	   or	   antagonizing	   ERβ	   enhances	   or	  inhibits	  tumor	  growth	  respectively.	  Hence,	  we	  suggest	  that	  ERβ	  is	  a	  central	  mediator	  of	  estrogen	  action	  in	  BCSCs.	  Although	  BCSCs	  are	  considered	  the	  apex	  of	  hierarchy	  in	  breast	  cancer	  progression,	  the	  origin	   of	   this	   unique	   cell	   subpopulation	   is	   not	   well	   established.	   Two	   alternative	   and	  contradictive	  models	  have	  been	  proposed	   to	  describe	   the	   tumor	  growth	  governed	  by	  BCSCs.	   In	   study	   II,	  we	   observe	   a	   large	   degree	   of	   shared	  mutations	   as	  well	   as	   similar	  spread	   of	   allele	   frequencies	   between	   BCSCs	   and	   the	   differentiated	   tumor	   cells	   by	  performing	  whole	  exome	  sequencing.	  We	  thereby	  conclude	  the	  existence	  of	  BCSCs	  as	  a	  population	  of	  cells	  dynamically	  and	  reversibly	  switching	  from	  differentiated	  tumor	  cells.	  In	   paper	   I,	   we	   observed	   that	   tamoxifen	   appears	   to	   be	   insufficient	   to	   reduce	  mammosphere	   formation	   and	   proliferation	   even	   from	   BCSCs	   derived	   from	   ERα+	  tumors.	  Therefore,	   in	  study	   III	  we	  conducted	  genome-­‐wide	   transcriptional	  analysis	   to	  explore	   potential	   mechanism	   posed	   by	   tamoxifen.	   Within	   the	   tamoxifen-­‐induced	  transcriptional	   pathways,	   ribosomal	   biogenesis	   and	   mRNA	   translation	   are	   the	   most	  
significantly	  and	  physiologically	  relevant	  pathways.	  We	  also	  identified	  induction	  of	  the	  key	   mTOR	   downstream	   targets	   S6K1,	   S6RP	   and	   4EBP1	   in	   BCSCs	   by	   tamoxifen	   on	  protein	   level.	   Using	   mTOR	   inhibitors	   along	   or	   in	   combination	   with	   tamoxifen,	   we	  observed	   significant	   reduction	   in	   mammosphere	   formation.	   We	   conclude	   that	  tamoxifen	   can	  activate	  mTOR-­‐signaling	  pathways	   in	  BCSCs	  associated	  with	  endocrine	  resistance.	  	  The	  rapid	  evolving	  genomic	  technologies	  and	  the	  advantages	  of	  using	  ex	  vivo	  modeling	  widens	   the	   possibilities	   to	   perform	   improved	   diagnostics	   for	   precision	   oncology.	   In	  study	   IV,	  we	   report	   a	   simple	   but	   robust	   superficial	   scraping	  method	   to	   collect	   viable	  primary	  cells	  from	  small	  tumors.	  Validation	  of	  scraping	  material	  has	  proven	  the	  method	  to	  be	  sufficient	  for	  analayses	  at	  DNA	  and	  mRNA	  level.	  By	  using	  this	  method	  for	  routine	  biobanking,	   the	   inclusion	   of	   resected	   tumors	   for	   fresh	   frozen	   sample	   storage	   could	  increase	  significantly	  from	  60%	  up	  to	  85%	  of	  the	  total	  breast	  cancers.	  	  In	  conclusion,	  studying	  BCSCs	  as	  a	  model	  system	  and	  as	  a	  target	  will	  be	  important	  for	  development	  of	  cancer	  therapies	  in	  advanced	  breast	  cancer.	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11 INTRODUCTION	  
1.1 BREAST	  CANCER	  INTRINSIC	  SUBTYPES	  AND	  HETEROGENEITY	  
1.1.1 Breast	  cancer	  intrinsic	  subtypes	  	  Breast	  cancer	  is	  a	  highly	  heterogeneous	  disease	  showing	  high	  degree	  of	  diversity	  among	  cancer	  patients	  and	  tumors.	  Traditionally,	  breast	  cancer	  heterogeneity	  has	  been	  observed	  by	  histopathological	  examination	  on	  the	  morphological	  level,	  and	  it	  is	   thought	   to	   affect	   clinical	   outcomes	   1,2.	   Recently,	   due	   to	   developments	   in	   gene	  expression	   technologies,	   the	   traditional	   classification	   methods	   based	   on	  immunohistochemistry	   and	   morphology	   have	   been	   refined,	   and	   are	   gradually	  being	  replaced	  by	  intrinsic	  molecular	  classification	  3,4.	  Breast	  cancer	  is	  one	  of	  the	  few	   tumor	   types	   that	   can	   be	   classified	   into	   distinctive	   molecular	   subtypes	   by	  microarray-­‐based	   gene	   expression	   analysis.	   This	   may	   lead	   to	   significant	  improvements	   in	   the	   design	   of	   individual	   therapies	   and	   therefore	   to	  improvements	  in	  breast	  cancer-­‐specific	  survival	  5,6.	  Based	   on	   the	   landmark	   work	   by	   Sorlie	   and	   colleagues	   who	   conducted	  comprehensive	  gene	  expression	  profiling	  3,	  breast	  cancer	  was	  demonstrated	  to	  be	  multiple	   biologically	   distinctive	   diseases	   each	   with	   its	   own	   unique	   molecular	  expression	  pattern	  7-­‐9.	  In	  addition,	  cluster	  analysis	  revealed	  that	  breast	  cancer	  has	  at	   least	   four	   characteristic	   molecular	   subtypes,	   including	   ER-­‐positive	   (luminal),	  human	   epidermal	   growth	   factor	   receptor	   2	   (HER2)-­‐enriched,	   basal-­‐like,	   and	  normal–like	   10.	   The	   luminal	   subtypes	   can	   be	   further	   divided	   into	   luminal	   A	   and	  luminal	  B,	   the	   latter	  with	  a	  higher	  proliferation	   rate.	  The	   subtypes	  have	   specific	  differences	  in	  terms	  of	  progression,	  response	  to	  treatment	  and	  preferential	  organs	  of	  distant	  metastasis.	  Approximately	  40%	  of	  all	  breast	  cancers	  are	  luminal	  A	  and	  20%	   are	   luminal	   B	   11,12.	   The	   subtypes	   can	   also	   be	   roughly	   separated	   based	   on	  immunohistochemistry	   13.	   However,	   based	   on	   gene	   expression,	   the	   important	  molecular	  distinction	  between	  the	  luminal	  A	  and	  B	  subtypes	  is	  higher	  expression	  of	  ER-­‐related	  genes	  and	  lower	  expression	  of	  HER2	  and	  proliferation-­‐related	  genes	  in	  luminal	  A11,12.	  In	  comparison,	  the	  luminal	  B	  subtype	  has	  lower	  expression	  of	  ER-­‐related	   genes,	   variable	   expression	   of	   HER2	   genes	   and	   higher	   expression	   of	   the	  proliferation-­‐related	  genes	  14.	  The	  HER2-­‐enriched	  subtype	  only	  contributes	  to	  10%–15%	  of	  all	  breast	  cancers.	  It	  is	   characterized	   by	   its	   low	   expression	   of	   the	   ER-­‐related	   genes	   but	   a	   high	  expression	   level	  of	   the	  HER2	  and	  proliferation-­‐related	  genes	  15.	  Of	  note,	   it	   is	  not	  true	   that	   all	   of	   the	   molecular	   HER2-­‐enriched	   subtypes	   are	   the	   same	   as	   the	  histopathologic-­‐defined	   HER2	   positive	   breast	   cancers,	   and	   vice	   versa.	   That	   is	  because	   not	   all	   HER2	   amplifications	   and	   overexpression	   are	   the	   result	   of	  HER2	  mutations.	  Consequently,	  around	  50%	  of	  clinically	  defined	  HER2-­‐positive	  tumors	  are	   not	   the	  HER2-­‐enriched	  molecular	   subtype,	   and	   are	   instead	   characterized	   as	  luminal	  subtypes	  with	  HER2-­‐positivity	  16.	  	  
2Around	  15%–20%	  of	  all	  breast	  cancers	  are	  categorized	  as	  the	  basal-­‐like	  subtype,	  which	   has	   low	   expression	   of	   the	   HER2	   and	   luminal-­‐related	   genes	   and	   high	  expression	  of	  the	  proliferation-­‐related	  cluster	  of	  genes	  17.	  It	  is	  usually	  not	  easy	  to	  distinguish	  between	   the	  basal-­‐like	   subtype	   and	   the	   triple-­‐negative	   subtype	   (e.g.,	  ER-­‐negative,	  PR-­‐negative,	  HER2-­‐negative),	  although	  most	  basal-­‐like	  breast	  cancers	  are	   triple-­‐negative,	   but	   not	   all	   the	   basal-­‐like	   cancers	   are	   triple-­‐negative.	   Finally,	  the	   normal-­‐like	   subtype	   is	   characterized	   by	   a	   gene	   expression	   pattern	   that	   is	  similar	   to	   that	   of	   normal	   breast	   tissue.	   It	   remains	  unclear	  whether	   this	   subtype	  represents	  a	  separate	  category	  with	  clinical	  significance	  or	  a	   technical	  artifact	  of	  the	  molecular	  analysis	  16.	  Hypotheses	   have	   been	   suggested	   to	   explain	   the	   intratumoral	   heterogeneity	   of	  breast	   cancer	   18.	   According	   to	   these	   theories,	   luminal	   lineage-­‐committed	  progenitors	   may	   contribute	   to	   form	   luminal	   and	   HER2-­‐enriched	   cancers,	   while	  basal-­‐like	  cancers	  may	  arise	  from	  stem-­‐cell-­‐like	  populations.	  However,	  data	  from	  gene	  expression	  pattern	  analysis	   followed	  by	  experimental	  explorations	   indicate	  that	   luminal	  progenitors	  also	  act	  as	  precursors	   to	   the	  basal-­‐like	  subtype.	  During	  the	  tumor	  forming	  process,	  genetic	  changes	  or	  epigenetic	  events	  may	  sequentially	  switch	  cellular	  phenotypes	  19-­‐21.	  Liu	  et	  al.	  reported	  that	  in	  luminal	  epithelial	  cells,	  loss	  of	  BRCA1	  or	  PTEN	   leads	  to	  loss	  of	  the	  luminal	  cell	  phenotype,	  and	  basal-­‐like	  cancers	  form	  as	  a	  result	  of	  oncogenetic	  transformation	  of	  these	  cells	  22.	  Since	  not	  all	  ER-­‐positive	  tumors	  and	  HER2-­‐enriched	  or	  basal-­‐like	  tumors	  are	  the	  same,	  we	  should	  bear	  in	  mind	  that	  there	  might	  be	  multiple	  ways	  to	  develop	  each	  of	  tumor	  types.	  Defining	   the	   breast	   cancer	   evolutionary	   pathways	   in	   humans	   is	   challenging,	   yet	  meaningful.	  The	  characterization	  would	  not	  only	  provide	  relevant	  information	  for	  breast	  cancer	  risk	  prediction	  and	  chemoprevention	  studies,	  but	  also	  be	  important	  for	   enriched	   knowledge	   of	   the	   breast	   cancer	   subtypes.	   Currently,	   only	   a	   few	  approaches	   have	   been	   implemented	   in	   tracing	   the	   evolutionary	   path	   of	   human	  cancer.	  One	  method	   is	   to	   collect	   a	   large	  amount	  of	   tumors	   at	  different	   stages	  of	  progression	   and	   analyze	   the	   molecular	   changes.	   The	   order	   of	   changes	   can	   be	  assembled	   based	   on	   the	   frequencies	   at	   which	   they	   are	   detected	   at	   specific	  progression	   steps	   24,25.	   Another	   approach	   is	   to	   analyze	   tumors	   by	   using	   next-­‐generation	   sequencing	   to	   detect	   somatic	  mutations	   or	   alterations	   at	   the	   genetic	  level.	  It	  is	  based	  on	  the	  assumption	  that	  some	  cells	  from	  the	  early	  stage	  of	  tumor	  will	   survive,	  and	   their	  existence	  and	   frequency	  within	  a	   tumor	  may	  uncover	   the	  steps	  of	  the	  tumor’s	  progression	  23.	  	  So	  far,	  knowledge	  about	  the	  breast	  cancer	  cell-­‐of-­‐origin	  is	  still	  limited,	  and	  more	  studies	  using	  current	  sequencing	  techniques	  are	  encouraged	  in	  this	  area.	  	  
1.1.2 Intra-­‐tumor	  heterogeneity	  Besides	  the	  numerous	  differences	  among	  tumor	  subtypes,	  breast	  cancer	  cells	  also	  display	   intratumoral	   heterogeneity.	   This	   heterogeneity	   includes	   various	  properties	   involved	   in	   tumorigenesis,	   for	   example,	   tumor	   invasion,	   angiogenesis	  and	  metastatic	  potential	  26.	  Intratumoral	  heterogeneity	  may	  partially	  reflect	  non-­‐
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genetic	  mechanisms	  such	  as	  the	  activity	  of	  signaling	  pathways	  and	  the	  fluctuation	  of	  protein	  expression	  in	  response,	  or	  adaptive	  responses	  that	  occur	  during	  tumor	  progression.	  It	  is	  believed	  that	  intra-­‐tumor	  heterogeneity	  can	  also	  help	  to	  partially	  explain	  inter-­‐tumor	  heterogeneity	  in	  breast	  cancer,	  since	  tumors	  are	  composed	  of	  mixtures	  of	  different	  cancer	  cells	  27.	  	  Cellular	  differentiation	  is	  achieved	  by	  epigenetic	  modifications	  such	  as	  chromatin	  modification	  changes	  and	  DNA	  methylation	  in	  specific	  cell	  types.	  For	  certain	  types	  of	  cancers,	   tumors	  arise	  from	  a	  group	  of	  stem-­‐cell-­‐like	  or	  progenitor	  cells	  with	  a	  preserved	   capacity	   to	   give	   rise	   to	   a	   more	   differentiated	   bulk	   tumor	   28,29.	   This	  model,	   the	   so-­‐called	   cancer	   stem	   cell	   theory,	   has	   also	   been	   applied	   to	   breast	  cancer,	  although	  the	  validity	  and	  interpretation	  of	  this	  model	  is	  still	  not	  clear.	  For	  example,	  a	  “gold	  standard”	  test	  currently	  in	  use	  to	  evaluate	  cancer	  stem	  cells	  is	  to	  perform	  an	  orthotropic	  transplantation	  assay.	  Tumor	  cell	  clones	  are	  transplanted	  into	  the	  mammary	  fat	  pad	  of	  immunodeficient	  mice	  to	  study	  their	  tumor-­‐initiating	  capacity.	  Use	  of	  this	  assay	  as	  a	  standard	  should	  be	  limited,	  because	  it	  is	  very	  much	  dependent	  on	  the	  assay	  model	  30,31	  and	  it	  fails	  to	  accurately	  reflect	  the	  behavior	  of	  cells	  in	  their	  true	  physiological	  environment.	  	  Intra-­‐tumor	   heterogeneity	   also	   poses	   a	   major	   challenge	   for	   effective	   treatment	  that	   can	  eradicate	   tumor	  cells	   thoroughly,	  because	   the	  cellular	  phenotype	  of	   the	  cell	  mixture	  changes	  constantly	  during	  tumor	  development32.	  Better	  understating	  of	   the	   tumor	   heterogeneity	   maintenance	   mechanism	   will	   be	   highly	   useful	   for	  improving	   therapies.	   Recent	   studies	   have	   also	   discovered	   cytokine	   signaling	  crosstalk	  between	  the	  tumor	  microenvironment	  and	  the	  cancer	  cells.	  For	  example,	  the	   IL-­‐6/JAK/STAT3	   pathway	  mediates	   tumor	   cell	   growth	   and	   survival	   through	  paracrine	   coordination.	   This	   knowledge	   provides	   the	   option	   of	   targeting	   this	  pathway	  as	  a	  new	  therapeutic	  strategy	  for	  a	  subset	  of	  breast	  cancers	  33,34.	  
1.2 ESTROGEN	   RECEPTOR	   ALFA	   AND	   ESTROGEN	   RECEPTOR	   BETA	   IN	  
BREAST	  CANCER	  Estrogens	  exert	  their	  function	  in	  the	  normal	  breast	  and	  in	  breast	  cancer	  through	  binding	   to	   two	   major	   estrogen	   receptor	   (ER)	   subtypes,	   ERα	   and	   ERβ	   35.	   They	  belong	   to	   the	   nuclear	   receptor	   (NR)	   superfamily	   composed	   of	   ligand-­‐regulated	  transcription	  factors	  36.	  ERα	  and	  ERβ	  are	  encoded	  by	  different	  genes	  and	  exhibit	  tissue-­‐	   and	   cell-­‐specific	   expression	   patterns	   37,38.	   They	   also	   display	   different	  transcriptional	  activity	  after	  ligand	  stimulation	  37,38.	  However,	  both	  receptors	  are	  co-­‐expressed	  in	  a	  number	  of	  tissues	  and	  can	  form	  either	  homo-­‐	  or	  hetero-­‐dimers	  to	  pose	  their	  functions39.	  Recent	  data	  also	  indicate	  that	  ERs	  form	  a	  complex	  with	  the	  progesterone	  receptor	  (PR)	  to	  mediate	  estrogen	  signaling	  40.	  In	  breast	  cancer,	  ER	  subtype-­‐specific	  expression	  together	  with	  other	  markers	  have	  been	  evaluated	  to	  define	  different	  subtypes	  of	  breast	  cancer.	  Variations	   in	  the	  expression	  of	  ERs	  are	  associated	  with	  different	  clinical	  outcomes	  41.	  Therefore,	  therapies	  provided	  to	  patients	   for	   hormone-­‐dependent	   cancers	   based	   on	   ER	   expression	   are	   central	   in	  improving	  outcomes.	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1.2.1 ER	  structures	  and	  their	  regulating	  mechanisms	  ERα	  and	  ERβ	  are	  encoded	  by	  two	  individual	  genes,	  ESR1	  and	  ESR2,	  respectively,	  which	   are	   located	   on	   different	   chromosomes	   36,37.	   Because	   they	   belong	   to	   the	  nuclear	  receptor	  superfamily,	  both	  receptors	  contain	  the	  evolutionarily-­‐conserved	  functional	   and	   structural	   domains	   that	   are	   typically	   observed	   in	   NR	   family	  members	   (Figure	  1).	   For	   example,	   they	   all	   have	   a	   six-­‐region	   structure	   including	  domains	  involved	  in	  DNA	  binding,	  ligand	  binding,	  dimerization	  and	  transcriptional	  activation.	  The	  ERs	  themselves	  share	  a	  high	  degree	  of	  similarity	  of	  the	  sequence	  in	  the	   DNA-­‐binding	   domains.	   A	   motif	   called	   a	   P-­‐box	   is	   identical	   between	   the	   two	  receptors.	   It	   is	   a	   critical	   region	   within	   the	   DNA	   binding	   domain	   (DBD)	   for	  receptor-­‐DNA	   recognition	   and	   specificity	   42,43.	   Thus,	   both	   receptors	  have	   similar	  specificity	  and	  affinity	  when	  binding	  to	  the	  estrogen	  responsive	  elements	  (EREs).	  The	  ligand	  binding	  domains	  (LBDs)	  are	  also	  conserved	  in	  both	  receptors,	  and	  they	  exhibit	   similar	   affinities	   for	   the	   natural	   endogenous	   estrogen	   17	   beta-­‐estradiol	  (E2).	   Nevertheless,	   ERα	   and	   ERβ	   display	   distinct	   affinities	   for	   some	   natural	  compounds	  and	  novel	  synthetic	  subtype-­‐selective	  ligands,	  and	  hence	  there	  is	  the	  possibility	  for	  them	  to	  be	  targeted	  by	  their	  selective	  agonists	  or	  antagonists	  42-­‐44.	  	  The	  trans-­‐activating	  functions	  of	  ERs	  are	  regulated	  by	  two	  structurally	  separated	  but	   mutually	   interacting	   transcription-­‐activation-­‐functions	   (AFs).	   The	   AFs	  facilitate	  the	  receptors	  to	  stimulate	  the	  transcription	  of	  estrogen-­‐related	  genes	  and	  mediate	   cell	   and	   promoter	   specificity	   36,37.	   The	   N-­‐terminal	   section	   contains	   the	  ligand-­‐independent	   activation	   function	   AF-­‐1,	   whereas	   the	   ligand-­‐dependent	  activation	   function	   AF-­‐2	   is	   located	  within	   the	   LBD	   at	   the	   C-­‐terminus.	   The	   AF-­‐1	  domains	  are	  very	  active	   in	  ERα	  on	  estrogen	   responsive	  promoters,	  whereas	   the	  activity	  of	  AF-­‐1	  is	  minimal	  in	  ERβ	  under	  the	  same	  conditions	  38,43.	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Figure	  1.	  Schematic	  representation	  of	  ERα,	  ERβ	  and	  their	  splice	  variants	  structure.	  	  The	   structural	   domains	   are	   color	   labeled	   and	   numbers	   of	   amino	   acids	   are	   indicated.	   The	   percentage	   of	  homologies	  between	  ERα	  and	  ERβ	  are	  presented.	  	  Functional	  domains	  are	  listed	  as:	  activation	  function	  1(AF1),	  activation	  function	  2(AF2),	  DNA	  binding	  domain	  (DBD)	  and	  ligand	  binding	  domain	  (LDB).	  From	  Thomas,	  C	  et	  
al.	  Nat	  Rev	  Cancer	  2011.	  Reprinted	  with	  permission	  from	  Nature	  Publishing	  Group.	  	  
Both	  ERα	  and	  ERβ	  have	  several	  isoforms	  that	  are	  derived	  from	  alternative	  splicing	  37,45.	   The	   splice	   variants	   have	   been	   compared	   to	   the	   wild-­‐type	   receptors	   for	  structural	   and	   functional	   differences	   in	   both	   normal	   and	   cancerous	   tissues.	   A	  number	  of	  ERα	  mRNA	  splice	  variants	  have	  been	  detected	  from	  numerous	  breast	  cancer	   cell	   lines	   and	   patient	   samples,	   although	   wild	   type	   ERα	   is	   always	  predominant	  45-­‐47.	  Some	  of	  the	  ERα	  variant	  isoforms	  have	  been	  shown	  to	  alter	  the	  clinical	  outcome	  of	  patients.	  For	  instance,	  the	  truncated	  isoform	  of	  ERα	  has	  been	  reported	  to	  confer	  endocrine	  resistance	  in	  breast	  cancer	  when	  co-­‐expressed	  with	  wild	  type	  48,49.	  	  ERβ,	  on	  the	  other	  hand,	  has	  far	  fewer	  identified	  isoforms.	  Only	  five	  splice	  variants	  have	  been	  reported,	  all	  as	  a	  result	  of	  alternative	  splicing	  of	   the	   last	  exon	  of	  wild	  type	  ERβ	  50,51.	  Most	  of	  these	  variants	  have	  been	  studied	  in	  cancers.	  For	  example,	  ERβcx	  (ERβ2)	  has	  been	  shown	  to	  modulate	  wild	  type	  ERβ	  (ERβ1)	  and	  antagonize	  wild-­‐type	   ERα	   transcriptional	   activity	   through	   hetero-­‐dimerization,	   which	   is	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highly	  associated	  with	  clinical	  outcomes	  in	  breast	  cancer	  51-­‐54.	  According	  to	  in	  vitro	  studies,	  wild-­‐type	  ERβ	  and	   its	   variant	   isoform	  ERβ2	  have	  been	   characterized	  as	  anti-­‐proliferative	   in	  ERα-­‐positive	   cell	   lines.	  Once	   overexpressed,	   they	   affect	   ERα	  transcriptional	   complexes,	   preventing	   or	   inhibiting	   ERα	   transcriptional	   activity	  and	  modulating	  the	  expression	  of	  ERα-­‐regulated	  genes	  51,55.	  The	   classical	   mechanism	   ERs	   use	   to	   implement	   their	   action	   involves	   a	   binding	  behavior,	   which	   means	   that	   when	   ligand	   binds	   to	   the	   LBD	   of	   the	   receptor,	   it	  induces	  ligand-­‐specific	  conformational	  changes	  of	  the	  receptor	  protein.	  It	  will	  then	  form	   either	   a	   heterodimer	   or	   a	   homodimer	   and	   binds	   to	   DNA	   through	   the	  sequence-­‐specific	   response	  elements	   (EREs),	  which	  consist	  of	   zinc	   fingers	  at	   the	  DBDs	  36,39.	  Once	  bound	  to	  EREs,	  the	  receptor	  dimers	  will	  recruit	  co-­‐activators	  or	  co-­‐repressors	   of	   different	   transcriptional	   factors	   depending	   on	   the	   shape	   of	   the	  ligand-­‐receptor	  complex.	  The	  receptor	  activity	   is	   influenced	  by	   these	  complexes,	  which	   either	   activate	   or	   repress	   downstream	   gene	   transcription.	   Co-­‐regulatory	  proteins	   are	   recruited	   in	   the	   process	   of	   complex	   formation,	   such	   as	   histone	  acetyltransferases	   that	  mainly	  work	  by	  modification	  of	   chromatin	  structure,	  and	  ubiquitin	  ligases	  that	  are	  recruited	  for	  the	  enhancement	  of	  transcription	  56,57.	  After	  the	   initiation	   step,	   post-­‐translational	   modifications	   will	   occur,	   among	   which,	  methylation	   or	   acetylation	   leads	   to	   further	   activation	   of	   the	   receptors	   and	  promotes	   the	   dissociation	   of	   the	   complex	   or	   the	   simultaneous	   ubiquitylation	  followed	  by	  degradation	  of	  the	  ERs	  39,42,43.	  	  Notably,	   in	   the	   absence	   of	   ligands,	   ERs	   can	   sometimes	   still	   elicit	   their	  transcriptional	   responses.	   For	   example,	   insulin-­‐	   like	   growth	   factor	   1	   receptor	  (IGF1R)	  or	  epidermal	  growth	   factor	  receptor	  (EGFR),	  which	  are	   the	  members	  of	  the	   hyperactive	   growth	   factor	   receptor	   family,	   can	   activate	   ERs	   by	   stimulating	  protein	  kinase	  cascades	  in	  the	  absence	  of	  ligands	  58.	  New	  evidence	  indicates	  that	  populations	   of	   ER	   subtypes	   located	   on	   the	   membrane	   or	   in	   the	   cytoplasm	   can	  mediate	   the	   rapid	   responses	   of	   estrogens	   59.	   Together	   with	   the	   involvement	   of	  other	   signaling	   pathways	   such	   as	  MAPK,	   PI3K,	   ERBB2,	   EGFR,	   SRC,	   IGFIR	   and	   G	  proteins,	   the	   activation	  of	   key	   components	  by	  ERs	   can	  be	  observed	  within	  3-­‐15	  minutes	   of	   estrogen	   treatment,	   and	   these	   further	   trigger	   other	   cascades	   to	  regulate	   gene	   expression	   by	   activating	   other	   transcriptional	   factors	   60-­‐62.	  Methylation	  of	  ERα	  by	  estrogen	  is	  also	  frequently	  observed	  in	  breast	  cancer.	  This	  results	  in	  the	  formation	  of	  complexes	  that	  are	  mainly	  composed	  of	  ERα,	  PI3K	  and	  SRC.	  Additionally,	  it	  also	  influences	  gene	  transcriptional	  events	  by	  activating	  AKT	  44.	  	  
1.2.2 Different	  transcriptional	  responses	  Although	   structurally	   homogenous,	   indicating	   that	   ERα	   and	   ERβ	   will	   share	  similarities	  in	  mechanical	  actions,	  it	  is	  not	  surprising	  to	  find	  functional	  differences	  in	   transcription	   responses	  elicited	  by	   the	   two	  different	  ERs.	  This	   is	  validated	  by	  microarray	   analysis	   of	   endogenous	   ER	   genes	   in	   breast	   cancer	   cells,	   where	  expression	   patterns	   reveal	   that	   the	   two	   ERs	   regulate	   some	   genes	   in	   common,	  regulate	  different	  genes	  and	  regulate	  some	  genes	  at	  different	  expression	  levels	  63.	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Moreover,	   in	   vitro	   experiments	   suggest	   that	   ERα	   and	   ERβ	   display	   divergent	  affinities	  and	  transcriptional	  responses	  to	  their	  specific	  selective	   ligands	  37.	  Even	  when	  binding	  to	  the	  same	  ligand,	  they	  have	  different	  response	  effects	  or	  signaling	  cascades	   that	   activate	   receptors	   at	   separate	   locations	   within	   the	   cells.	   17β-­‐estradiol	  serves	  as	  a	  classical	  agonist	  for	  both	  ERs,	  and	  can	  induce	  conformational	  changes	  in	  the	  receptors	  that	  result	  in	  different	  binding	  selectivity.	  In	  ERα,	  it	  can	  provoke	   the	  binding	  of	  only	  co-­‐activators	  compared	   to	  ERβ,	  which	  recruits	  both	  co-­‐activators	  and	  co-­‐repressors	  65.	   In	  contrast	  with	  17β-­‐estradiol,	   tamoxifen	  acts	  as	   a	   classical	   antagonist	   to	   ERα	   by	   recruiting	   co-­‐repressors	   after	   binding	   to	   the	  receptor,	   but	   it	   does	   not	   have	   the	   same	   effect	   when	   binding	   to	   ERβ	   64,65.	   This	  implies	  a	  relative	  balance	  between	  co-­‐activator	  and	  co-­‐repressor	  expression	  that	  can	   affect	   the	   activity	   of	   agonist	   and	   antagonist	   in	   the	   cells.	   Additionally,	   other	  studies	   reported	   that	   ERα	   and	   ERβ	   differentially	   regulate	   MYC,	   a	   nuclear	  transcription	   factor	  with	  mitogenic	   effect	   that	   can	   induce	   cell	   cycle	   progression	  66,67.	  
1.2.3 Estrogen	   and	   ERs	   in	   the	   normal	   mammary	   gland	   and	   in	   breast	  
cancer	  progression	  To	  date,	  our	  knowledge	  of	  the	  role	  of	  ERs	  in	  human	  mammary	  gland	  development	  is	  still	  lacking	  in	  fundamental	  data.	  Only	  pieces	  of	  key	  information	  are	  available	  to	  fill	   in	   the	   gaps	   in	   our	   knowledge	   of	   estrogen	   signaling.	   Based	   on	   previous	  observations,	   ERα	   is	   mostly	   located	   in	   the	   inner	   layer	   of	   epithelial	   cells	   or	   the	  external	  layer	  of	  myoepithelial	  cells	  lining	  the	  intralobular	  ducts	  in	  premenopausal	  women.	   In	   comparison,	   the	   distribution	   of	   ERβ	   is	   more	   widespread,	   in	   both	  epithelial	  and	  stromal	  cells	  68.	  In	  postmenopausal	  women,	  ERα	  expression	  is	  only	  found	  in	  less	  than	  10%	  of	  mammary	  epithelial	  cells	  whereas	  ERβ	  is	  expressed	  in	  more	   than	   50%	   of	   epithelial	   cells.	   The	   stromal	   component	   in	   postmenopausal	  women	  also	  expresses	  higher	  levels	  of	  nuclear	  ERβ	  but	  not	  ERα	  69.	  Based	  on	  in	  vivo	  studies,	   ERα	   has	   been	   proven	   to	   be	   responsible	   for	   cellular	   proliferation	   as	   an	  indirect	   effect	   after	   estrogen	   stimuli	   70.	   ERβ	   represses	   proliferation	   and	   is	   pro-­‐apoptotic	   when	   it	   is	   overexpressed	   in	   vitro	   37,71.	   This	   indirect	   effect	   of	   ERα	   on	  promoting	   proliferation	   has	   been	   reported	   to	   occur	   through	   a	   paracrine	  mechanism	   involving	   ERα-­‐positive	   cells70,	   although	   this	   has	   only	   been	  demonstrated	   in	   mouse	   models.	   A	   number	   of	   paracrine	   mediators	   that	   might	  account	   for	   the	   effects	   of	   estrogens	   have	   been	   identified	   from	   other	   studies.	  Among	  these,	   the	  receptor	  activator	  of	  amphiregulin	   is	  suggested	  to	  be	  a	  critical	  paracrine	  mediator	  for	  ERα72.	  In	  breast	  cancer,	  a	  few	  reports	  have	  concluded	  that	  ERα	  might	  regulate	  cancer	  cell	  migration	   and	   invasion.	   ERα	   represses	   nuclear	   factor	   (NF)-­‐κB	   and	   activator	  protein	   1	   (AP-­‐1),	   but	   activates	   and	   increases	   E-­‐cadherin	   expression	   by	   down-­‐regulating	   its	   repressors	   to	   further	   control	   the	   epithelial-­‐mesenchymal	  transformation	   (EMT)73,74.	   Similar	   to	   ERα,	   ERβ	   also	   mediates	   cell	   migration.	   In	  prostate	   cancer,	   down-­‐regulation	   of	   ERβ	   is	   found	   to	   induce	   EMT,	   which	   is	  consistent	  with	  the	  fact	  that	  many	  prostate	  cancers	  experience	  a	  loss	  of	  ERβ.	  When	  ERβ	   is	   activated	   by	   its	   specific	   ligand	   3β-­‐adiol,	   a	   metabolite	   of	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dihydrotestosterone,	  the	  expression	  of	  E-­‐cadherin	  will	  enable	  the	  prostate	  cancer	  cells	  to	  sustain	  an	  epithelial	  phenotype	  and	  repress	  invasion75.	  In	  addition,	  knock-­‐out	  of	  ERβ	  can	  decrease	  E-­‐cadherin	  expression	  in	  mouse	  mammary	  epithelial	  cells	  76. The	   same	  observations	  may	  apply	   to	   the	   increased	  expression	  of	   integrin	  α1and	  β1	  due	  to	  ERβ,	  which	  enhances	  breast	  cancer	  cell	  adhesion	  in	  culture	  77.	  These	  facts	  all	  support	  the	  idea	  that	  ERβ	  maintains	  a	  differentiated	  epithelial	  phenotype	  through	  the	  inhibition	  of	  EMT.	  
1.3 ENDOCRINE	   THERAPY	   FOR	   BREAST	   CANCER	   AND	   POSSIBLE	  
MECHANISMS	  OF	  RESISTANCE	  In	   the	   previous	   section,	   we	   have	   discussed	   breast	   cancer	   as	   a	   heterogeneous	  disease	   composed	   of	   multiple	   subgroups	   with	   their	   distinctive	   molecular	  backgrounds,	   different	   risk	   factors	   for	   incidence	   and	   disease	   progression	   and	  preferred	  organ	  sites	  for	  metastases.	  Across	  all	  of	  the	  breast	  cancer	  types,	  at	  least	  70%	   of	   tumors	   are	   classified	   as	   ERα-­‐positive	   78.	   This	   phenotype	   has	   been	  explained	   by	   the	   sustained	   exposure	   to	   endo-­‐	   or	   exogenous	   estrogen	   through	  estrogen	   receptors	   79.	   Thus,	   interfering	  with	   estrogen	   and	   receptors	   has	   been	   a	  cornerstone	  of	  treating	  breast	  cancer	  for	  over	  a	  century.	  Synthesis	  of	  estrogen-­‐ER	  binding	   site	   competitive	   inhibitors	   first	   occurred	   in	   the	   1970s,	   including	   the	  selective	   estrogen	   receptor	   modulator	   (SERM)	   tamoxifen,	   which	   successfully	  increased	  the	  survival	  rate	  of	  breast	  cancer	  patients.	  Today,	  these	  agents	  are	  still	  used	  as	  primary	  therapy	  for	  breast	  cancer	  80.	  Tamoxifen	  used	  as	  adjuvant	  therapy	  can	  reduce	  by	  one-­‐third	  the	  number	  of	  annual	  breast	  cancer	  deaths	  and	  it	  halves	  the	  recurrence	  rate.	  It	  contributes	  to	  a	  significant	  decrease	  (around	  30%)	  in	  breast	  cancer	   mortality	   81.	   Other	   new,	   effective	   endocrine	   synthetics	   have	   been	  developed	   in	   recent	   years	   to	   target	   estrogen	   actions,	   such	   as	   the	   aromatase	  inhibitors	   and	   ER	   signaling	   antagonists	   82,83.	   The	   aromatase	   inhibitors	   act	   by	  blocking	   the	   enzyme	   aromatase,	   which	   catalyze	   the	   hormone	   androgen	   into	  estrogen	  82,84.	  Fulvestrant,	  a	  complete	  ER	  antagonist,	  can	  accelerate	  degradation	  of	  the	  ER	  and	   serve	   as	   second-­‐line	   therapy	   for	  patients	  who	   failed	   in	   the	  previous	  endocrine	  therapy	  85,86.	  	  However,	   a	   crucial	   issue	   about	   tamoxifen	   administration	   is	   that	   33%	  of	  women	  treated	  with	   tamoxifen	   for	  5	  years	  will	  develop	  a	   recurrence	  within	  15	  years	   81,	  which	  means	  that	  around	  25%	  of	  all	  breast	  cancers	  become	  endocrine-­‐resistant.	  This	   observation	   raises	   two	  major	   challenges	   for	   improvement	   of	   breast	   cancer	  treatment:	   1.	   Identifying	   new	   therapeutic	   targets	   against	   endocrine-­‐resistant	  cancer,	   and	   2.	   Developing	   more	   specific	   biomarkers	   for	   predicting	   therapeutic	  response	  to	  endocrine	  therapy.	  	  
1.3.1 Molecular	  mechanisms	  of	  resistance	  The	   primary	   mechanism	   of	   intrinsic	   resistance	   to	   tamoxifen	   is	   loss	   of	   ERα	  expression.	  Other	  mechanisms	  are	  supposed	  to	  account	  for	  acquired	  resistance	  to	  tamoxifen	   due	   to	   the	   long-­‐term	   exposure	   87.	   Many	   studies	   reporting	   these	  potential	  molecular	  mechanisms	  were	  based	  on	  observations	  derived	   from	  ERα-­‐
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positive	  breast	  cancer	  cell	  lines	  or	  variants	  of	  the	  cell	  lines	  selected	  for	  adaptation	  to	  sustained	  exposure	  to	  estrogen	  or	  absence	  of	  estrogen.	  Therefore,	  conclusions	  drawn	  from	  such	  models	  have	  several	  limitations	  since	  cell	  lines	  are	  induced	  to	  be	  tamoxifen	  resistant	  in	  vitro	  rather	  than	  exhibiting	  the	  actual	  resistance	  developed	  in	  breast	  cancer	  patients.	  The	  accuracy	  and	  validity	  of	  the	  proposed	  mechanisms	  should	   also	  be	  questioned	   since	   the	   in	   vivo	  condition	  with	   an	   epithelial–stromal	  tumor	  microenvironment	  probably	  modulates	  tamoxifen	  sensitivity	  88,89,	  and	  it	  is	  unlikely	  that	  ERα	  positive	  breast	  cancer	  cell	  lines	  can	  truly	  reflect	  the	  range	  of	  ER-­‐positive	  phenotypes	  that	  can	  develop	   in	  vivo.	   In	  spite	  of	  the	  potential	  limitations,	  cell	   line	  models	   are	   still	   widely	   used	   to	   study	   the	   candidate	   genes	   involving	   in	  estrogen	  signaling	  or	  regulation	  of	  cell	  proliferation.	  The	  concepts	  and	  hypotheses	  developed	  are	  still	  important	  in	  providing	  indications	  for	  tamoxifen	  resistance	  in	  patients	   and	   provide	   a	   basis	   for	   modeling	   new	   therapeutic	   approaches.	  Deregulation	  of	  estrogen	  signaling	  is	  a	  major	  mechanism	  for	  tamoxifen	  resistance,	  although	   other	   mechanisms	   contributing	   to	   the	   resistance	   should	   also	   be	  investigated,	   such	   as,	   cancer	   cells	   that	   have	   developed	   alternative	   proliferation	  and	  survival	  mechanisms	  87,90.	  
1.3.2 Targeting	  ER	  signaling	  and	  co-­‐regulators	  ERα	  expression	  is	  currently	  the	  principal	  biomarker	  and	  indicator	  of	  response	  to	  endocrine	   therapies	   like	   tamoxifen,	   since	   ER-­‐negative	   breast	   cancers	   rarely	  respond	  to	  them.	  Earlier	  publications	  tried	  to	  state	  that	  the	  potential	  mechanisms	  of	   acquired	   resistance	   were	   due	   to	   ERα	  mutations	   and	   loss	   of	   ERα	   expression.	  However,	   later	   validation	   studies	   found	   that	   ERα	   mutations	   only	   appeared	   in	  fewer	   than	  1%	  of	   ER	  positive	   tumors	   38,91,92	  while	   only	   15%-­‐20%	  of	   tamoxifen-­‐resistant	  tumors	  were	  lacking	  ERα	  expression	  93.	  Recently,	  Shi	  et	  al.	  reported	  that	  in	  the	  presence	  of	  ERα,	  its	  truncated	  variant	  ERα36	  was	  associated	  with	  a	  reduced	  response	   to	   tamoxifen	   49.	   ERβ	   and	   other	   variants	   also	   play	   potential	   roles	   in	  tamoxifen	  responsiveness,	  especially	  when	  ERα	  is	  absent	  94.	  In	  addition,	  estrogen-­‐related	  receptor	  (ERRγ)	  was	  found	  to	  be	  overexpressed	  in	  lobular	  invasive	  breast	  cancer	  and	  can	  induce	  tamoxifen	  resistance	  95.	  	  In	   the	   previous	   section,	   we	   have	   described	   the	   mechanisms	   whereby	   ERα	  regulates	   gene	   expression.	   This	   occurs	   mainly	   through	   protein-­‐protein	  interactions	  with	  other	  transcriptional	  factors	  such	  as	  NF-­‐κB,	  Ap1	  and	  specificity	  protein	  1	  (Sp1).	  Of	  these,	  NF-­‐κB	  and	  Ap1	  transcriptional	  activity	  are	  reported	  to	  be	  correlated	   with	   endocrine	   resistance	   96-­‐98.	   Post-­‐translational	   modifications	  including	   sumoylation,	   phosphorylation	   and	   methylation	   also	   affect	   ERα	  function99	   by	   changing	   its	   interactions	   with	   other	   transcriptional	   proteins	   and	  cytoplasmic	  signaling	  components	  100,101.	  
1.3.3 Receptor	  tyrosine	  kinase	  signaling	  Some	   early	   observations	   identified	   the	   crosstalk	   between	   ER	   signaling	   and	  receptor	  tyrosine	  kinase	  signaling	  by	  showing	  that	  the	  expression	  of	  ER	  correlates	  with	   the	   epidermal	   growth	   factor	   receptor	   (EGFR)	   family	   members	   including	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EGFR	  and	  ERBB2	  102.	  In	  vitro	  studies	  showed	  that	  growth	  factors	  and	  insulin	  like	  growth	   factors	   can	  modulate	   tamoxifen	   susceptibility	   in	   breast	   cancer	   cells	   103.	  Increased	  expression	  of	  those	  receptors	  could	  drive	  tamoxifen	  resistance	  104-­‐106	  by	  activating	   their	  downstream	  signaling	  pathways,	  particularly	   the	  effectors	   in	   the	  PI3K	  pathways	  107-­‐109.	  The	   deregulation	   of	   these	   signaling	   pathways	   can	  be	   classified	   into	   two	   groups.	  First,	  genetic	  or	  epigenetic	  modifications	  might	  take	  place.	  Methylation	  or	  loss	  of	  PTEN	  (a	  tumor	  suppressor	  inhibiting	  the	  PI3K	  pathway),	  amplification	  of	  ERBB2	  and	   mutations	   of	   PIK3CA	   (it	   encodes	   a	   catalytic	   subunit	   of	   PI3Ks)	   can	   all	  contribute	   to	   the	  deregulation	   92,110.	  Second,	  abnormality	  of	  upstream	  regulators	  of	  these	  pathways	  might	  occur.	  For	  instance,	  loss	  of	  PTEN	  expression	  and	  ERBB2	  overexpression	   are	   associated	   with	   AKT	   activation.	   IGFR1	   and	   ERBB3	   are	   also	  found	  to	  be	  activated	  as	  a	  consequence	  of	  the	  absence	  of	  PTEN	  92,110.	  Although	  the	  mechanism	   behind	   tamoxifen	   resistance	   mediated	   by	   these	   factors	   has	   not	   yet	  been	   fully	  elucidated,	   there	  are	  some	  clues	  as	   to	   the	  cause	  of	   the	  resistance.	  For	  example,	   ERK	   activation	   decreases	   ERα	   expression,	   ER-­‐mediated	   repression	   of	  EGFR	   subsequently	   activates	   mitogenic	   signaling	   cascades,	   and	   ligand-­‐independent	   activation	  of	  ER	   and	   its	   co-­‐activators	   through	  phosphorylation	   and	  constitutive	   activation	   of	   survival	   signaling	   further	   inhibit	   apoptosis	   44.	   ERBB2	  overexpression	  is	  one	  of	  the	  well-­‐established	  mechanisms	  of	  endocrine	  resistance.	  It	  is	  known	  that	  amplification	  of	  ERBB2	  and	  loss	  of	  transcriptional	  repressors	  are	  mainly	   responsible	   for	   increased	   expression	   of	   this	   receptor111-­‐113.	   On	   the	  contrary,	  ERBB2	  repression	  is	  correlated	  with	  increased	  survival	  after	  tamoxifen	  treatment	   112.	   In	   addition,	   the	   members	   of	   tyrosine	   kinases	   in	   SRC	   family,	  particularly	  downstream	  targets	  of	  SRC	  are	  implicated	  in	  tamoxifen	  resistance	  in	  breast	  cancer	  114-­‐116.	  
1.3.4 Cell	  cycle	  regulators	  Neo-­‐adjuvant	   and	   adjuvant	   endocrine	   therapies	   have	   been	   supported	   by	  experimental	  model	  systems	  with	  clinical	  correlations	  as	  being	  both	  cytostatic	  and	  cytotoxic	   117.	   These	   therapies	   can	   lead	   to	   decreased	   proliferation	   and	   increased	  cell	  apoptosis.	   In	  cell	   culture,	  estrogen	  antagonist	   treatment	  with	  agents	  such	  as	  tamoxifen	   or	   aromatase	   inhibitors	   can	   result	   in	   a	   G1	   phase-­‐specific	   cell	   cycle	  arrest,	  which	  leads	  to	  the	  activation	  of	  the	  cellular	  stress	  response	  and	  apoptosis	  in	   breast	   cancer	   cells,	   and	   consequently	   a	   reduced	   cell	   growth	   rate	   118.	   Not	  surprisingly,	   in	  vitro	  data	  has	  shown	  that	  cMYC,	  cyclin	  E	  and	  cyclin	  D	  are	  crucial	  for	  the	  anti-­‐estrogen	  effects	  on	  cell	  cycle	  progression,	  especially	  in	  controlling	  the	  G1	   phase	   arrest	   and	   apoptotic	   initiation.	   Once	   their	   expression	   levels	   become	  aberrant,	  endocrine	  treatment	  resistance	  might	  occur	  that	   further	  contributes	  to	  reduced	  tamoxifen	  responsiveness	  in	  breast	  cancer	  patients	  119-­‐124.	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1.4 BREAST	  CANCER	  STEM	  CELLS	  AND	  THEIR	  IMPACT	  ON	  BREAST	  CANCER	  
PROGNOSIS	  
1.4.1 The	  cancer	  stem	  cell	  hypothesis	  Even	   though	   it	  was	  developed	  only	   recently,	   the	  hypothesis	  of	   cancer	  stem	  cells	  (CSCs)	   has	   had	   considerable	   impact	   on	   cancer	   research	   (Figure	   2).	   With	   the	  current	   advanced	  new	   techniques	  and	  animal	  models,	   direct	   tests	   and	  validated	  results	  have	  been	  quickly	  produced	  from	  cancer	  stem	  cell	  research.	  The	  major	  idea	  of	   this	   hypothesis	   is	   that	   solid	   tumors	   contain	   a	   unique	   subset	   of	   cellular	  components	  displaying	  normal	  stem	  cell	  properties.	  These	  include:	  the	  capacity	  to	  self-­‐renew,	   the	   ability	   to	   differentiate	   under	   certain	   stimuli,	   active	   telomerase	  expression,	   active	   anti-­‐apoptotic	   pathways	   and	   the	   potential	   to	   migrate	   and	  metastasize	  125.	  CSCs	  were	  first	  discovered	  by	  Dick	  and	  colleagues	  in	  human	  acute	  myeloid	  leukemia	  29,126.	  Gradually,	  CSCs	  existence	  was	  identified	  from	  other	  types	  of	  cancer.	  Although	  they	  only	  make	  up	  a	  small	  proportion	  of	  the	  tumor	  mass,	  CSCs	  are	   highly	   potent	   in	   their	   ability	   to	   give	   rise	   to	   other	   types	   of	   tumor	   cells	   and	  create	   hierarchically	   integrated	   tumors	   28,29,126-­‐128.	   Accumulating	   data	   suggests	  that	   CSCs	   are	   resistant	   to	   conventional	   therapies	   and	   play	   an	   important	   role	   in	  mediating	   tumor	   metastasis	   and	   relapse	   129-­‐132.	   Hence,	   the	   CSCs	   hypothesis	  provides	   a	   plausible	   explanation	   for	   treatment	   failure	   and	   attracts	   increasing	  attention	   in	   current	   research.	   The	   complexity	   and	   heterogeneity	   of	   cancer	  indicates	  that	  the	  mechanisms	  for	  resistance	  and	  recurrence	  caused	  by	  CSCs	  vary	  depending	   on	   the	   type	   of	   cancer.	   Therefore,	   specific	   target	   therapies	   against	  different	  types	  of	  tumors	  may	  be	  required.	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Figure	   2.	   The	   hypothesis	   of	   tumorigenesis	   governed	   by	   CSC.	   CSC	   generates	   a	   bulk	   tumor	   based	   on	   its	   self-­‐renewal	  properties	  and	  proliferative	  potential.	  Initially,	  tumor	  growth	  might	  be	  driven	  by	  a	  certain	  CSC1,	  along	  with	  the	  tumor	  progression,	  another	  distinct	  CSC2	  may	  evolve	  from	  CSC1	  and	  take	  over	  the	  capacity	  to	  form	  tumor	   in	  the	   later	  stage.	  From	   Jane	  E,	  V.	  et	  al.	  Nat	  Rev	  Cancer	  2008.	  Reprinted	  with	  permission	  from	  Nature	  Publishing	  Group.	  	  
1.4.2 Identify	  BCSCs	  and	  their	  roles	  in	  breast	  cancer	  biology	  The	  applicability	  of	  the	  CSCs	  hypothesis	  in	  solid	  tumors	  remains	  in	  heated	  debate.	  In	   2003,	   CSCs	   from	   human	   breast	   cancers	   were	   first	   identified	   by	   Al-­‐Hajj	   and	  collaborators	  28.	  Thereafter,	  CSCs	  have	  been	  identified	  in	  most	  of	  the	  solid	  cancers,	  including	  brain,	  colon,	  pancreatic,	  head	  and	  neck,	  and	  others	  127,128,133.	  Following	  the	   work	   of	   Al-­‐Hajj	   et	   al.,	   researchers	   isolated	   subpopulations	   of	   cells	   from	  primary	  tumors	  and	  pleural	  effusions	   from	  breast	  cancer	  patients.	  Only	  the	  cells	  carrying	  the	  phenotype	  of	  ESA+CD44+CD24−/low	  were	  able	  to	  reform	  tumors	  when	  transplanted	  in	  as	  few	  as	  100	  cells	  into	  the	  mammary	  fat	  pad	  of	  NOD/SCID	  mice,	  while	   larger	   populations	   of	   other	   types	   of	   cells	   retained	   their	   non-­‐tumorigenic	  properties	  28.	  Therefore,	  the	  cell	  surface	  markers	  CD44+/CD24-­‐	  were	  suggested	  as	  a	  combination	  that	  can	  be	  used	  to	   identify	  breast	  cancer	  CSCs	  (BCSCs).	  Later	  on,	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Ginestier	   et	   al.	   described	   another	   small	   subset	   of	   CD44+/CD24-­‐	   cells	   with	   an	  additional	   ALDH1-­‐high	   phenotype	   that	   were	   highly	   tumorigenic,	   proven	   by	  showing	   that	   injection	   of	   only	   20	   cells	   into	   NOD/SCID	   mice	   was	   sufficient	   to	  initiate	   tumor	   formation134.	   The	  ALDH1-­‐positive	   cells	   not	   only	   recapitulated	   the	  heterogeneity	  of	  the	  parental	  tumor,	  displaying	  non-­‐tumorigenic	  components,	  but	  also	   repeated	   this	   process	   upon	   serial	   passaging	   in	   the	   mouse	   model.	   This	  recreation	  of	  the	  original	  tumor	  demonstrated	  both	  their	  differentiation	  and	  self-­‐renewal	   potential	   as	   stem	   cells.	   Further	   research	   has	   focused	   on	   the	   clinical	  implications	   of	   ALDH1	   expression	   in	   breast	   cancer,	   indicating	   that	   its	   presence	  correlates	   with	   poor	   prognosis	   in	   breast	   cancer	   patients	   134,135.	   	   Recent	  publications	  also	  added	  additional	  information	  about	  the	  CD44+/CD24-­‐	  population	  
in	  vivo,	   showing	   that	   they	  are	  enriched	   in	  basal-­‐like	   tumors	  as	  well	  as	   in	  BRCA1	  tumors	  136,	  and	  that	  they	  indicate	  a	  poor	  prognosis137,138.	  Notably,	   several	   articles	   have	   mentioned	   successful	   generation	   of	   BCSCs	   from	  either	  breast	   cancer	  patient-­‐derived	  material	  or	   from	  breast	   cancer	   cell	   lines	  by	  using	  verified	  selectable	  markers	  139,140.	  In	  the	  other	  hand,	  the	  estimation	  of	  BCSCs	  frequency	  varies	  extensively	  in	  different	  cell	  lines.	  For	  example,	  the	  breast	  cancer	  cell	   line	  MDA-­‐MB-­‐231	  has	  been	  reported	  to	  contain	  85%	  CD44+/CD24-­‐	  cells,	  but	  only	  0.88%	  are	  ALDH1-­‐positive,	  and	  the	  MCF7	  cell	   line	  has	  no	  CD44+/CD24-­‐	  cell	  populations	  but	  0.2%	  of	   the	  cells	  are	  ALDH1-­‐positive139,141.	  This	  huge	  difference	  signifies	   that	   none	   of	   these	   identified	   BCSCs	   markers	   are	   universal	   to	   breast	  cancer.	  Thus,	  continuing	  the	  search	  for	  novel	  markers	  or	  combining	  new	  markers	  with	  the	  existing	  markers	  will	  presumably	  improve	  the	  isolation	  of	  BCSCs	  and	  lead	  to	  understanding	  of	   their	   implications	   in	  breast	   cancer	  progression,	   relapse	  and	  resistance.	  
1.4.3 The	  role	  of	  BCSCs	  in	  metastasis	  Breast	  cancer	   is	  highly	   treatable	  with	  a	  very	  promising	  5-­‐year	  survival	   rate,	   if	   it	  can	  be	  detected	  in	  the	  early	  stages.	  However,	  good	  outcomes	  become	  rare	  once	  the	  disease	  metastasizes	  142,143.	  The	  process	  of	  metastasis	  has	  been	  well	  established	  as	  a	   stepwise	   procedure.	   In	   general,	   the	   cancer	   cells	   will	   first	   detach	   from	   the	  primary	   tumor	   and	   enter	   the	   bloodstream	   or	   the	   lymphatic	   circulation	   via	  intravasation.	   Carried	   by	   the	   circulatory	   system,	   surviving	   cells	   will	   reach	   a	  secondary	  site,	  and	  then	  extravasate	  into	  the	  tissue.	  These	  cancer	  cells	  are	  highly	  potent	   in	   initiating	   colony	   growth,	  which	   forms	   a	  micro-­‐metastasis	   followed	   by	  subsequent	  angiogenesis	  to	  promote	  macro-­‐metastasis	  progression142,144,145.	  	  Interestingly,	  metastatic	   lesions	  are	   lethal,	   yet	   it	  has	  been	  proven	   to	  be	  a	  highly	  inefficient	   process.	   Luzzi	   and	   colleagues	   used	   an	   in	   vivo	   video	   microscopy	   to	  observe	   the	   process.	   Although	   exemplified	   by	   melanoma,	   a	   highly	   metastatic	  tumor,	   only	   0.02%	   of	   the	   injected	   cells	   could	   successfully	   induce	   a	   metastatic	  cascade	  in	  the	  targeted	  organ	  146.	  The	  incidence	  of	  cells	  able	  to	  form	  metastases	  as	  reported	  previously	  corresponds	  to	  the	  proportion	  of	  CSCs	  in	  cancers.	  In	  fact,	  in	  an	  eloquent	   review	   by	   Croker	   and	   Allan,	   they	   presumed	   that	   in	   breast	   cancer	   the	  inefficiency	   is	   on	   account	   of	   the	   absence	   of	   a	   favorable	  microenvironment	   for	   a	  secondary	   growth	   in	  distant	   tissue,	   hence	  preventing	   the	  majority	   of	   circulating	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cancer	  cells	   from	  anchoring	  147.	  However,	   the	  potency	  of	  CSCs	  makes	   them	  ideal	  metastasis-­‐initiating	  cells,	  as	  they	  exhibit	  properties	  like	  self-­‐renewal,	  capacity	  to	  inhabit	  many	   different	  microenvironments	   and	   inherent	   resistance	   to	   apoptosis	  and	  conventional	  treatments.	  	  Meanwhile,	   proof	   that	   BCSCs	   are	   responsible	   for	   breast	   cancer	   metastasis	   has	  been	   collected	   from	   two	   perspectives.	   First,	   it	   has	   been	   shown	   that	   the	   EMT	   is	  coupled	   with	   the	   formation	   of	   BCSCs	   148,149.	   	   An	   EMT	   is	   an	   initial	   step	   in	   the	  metastatic	  progress.	  Chemotherapy	   induces	  residual	  breast	  cancer	  cells	   to	  adopt	  both	  a	  BCSC	  phenotype	  and	  EMT	  features.	  Normal	  mammary	  epithelial	  cells	  also	  display	   enhanced	  BCSCs	   properties	  when	   undergoing	   an	   EMT	   149.	   Regulators	   of	  EMT	   expression	   also	   drive	   non-­‐tumorigenic	   cancer	   cells	   towards	   a	   tumorigenic	  status129,150,151.	   Moreover,	   signaling	   pathways	   involved	   in	   MET,	   the	   reverse	  process	   of	   EMT,	   which	   is	   an	   essential	   step	   in	   the	   last	   stage	   of	   metastasis,	   also	  induce	   stem-­‐cell-­‐like	   characteristics	   in	   breast	   cancer	   cells	   152.	   Additionally,	  CD44+/CD24-­‐	   defined	   BCSCs	   subpopulations	   not	   only	   boost	   the	   incidence	   of	  metastasis	   when	   administrated	   through	   mice	   tail	   veins	   153,	   but	   also	   co-­‐express	  EMT	  markers	  and	  furthermore	  reduce	  the	  burden	  for	  metastatic	  events	  149.	  Breast	  cancer	  metastases	  that	  develop	  at	  different	  sites	  seem	  to	  always	  carry	  the	  BCSCs	  CD44+	  profile	   in	  mouse	  xenograft	  studies	   154-­‐156.	  The	  metastatic	   lesions	  at	  orthotopic	   sites	  have	  been	  confirmed	   to	  express	  high	   levels	  of	  CD44,	  which	  was	  experimentally	  demonstrated	  to	  play	  a	  central	  role	  in	  the	  attachment	  of	  metastatic	  breast	   cancer	   cells	   to	   the	   bone	  marrow	   endothelial	   cells	  when	   interacting	  with	  osteopontin	   156.	   A	   study	   on	   a	   spontaneous	   lung	   metastasis	   also	   found	   the	  generated	  tumor	  had	  a	  similar	  rate	  of	  CD44	  positivity	  as	  compared	  to	  the	  primary	  tumor	   157.	   In	  addition,	  we	  and	  other	   research	  groups	  have	  described	  BCSCs	   that	  are	  ER-­‐	  independent	  of	  parental	  tumor	  ER	  status.	  It	  is	  not	  rare	  that	  ER-­‐	  metastatic	  cancers	   are	   found	   in	   ER+	   patients	   158,159,	   which	   demonstrates	   the	   metastatic	  potential	  of	  ER-­‐	  BCSCs	  or	  alternatively	  provides	  a	  possible	  explanation	  of	  subtype	  shifting.	   Expression	   of	   the	   ALDH1	   isoform	   ALDH1A3	   is	   also	   associated	   with	  metastasis	  160,161.	  
1.4.4 The	  role	  of	  BCSCs	  in	  conventional	  therapy	  resistance	  Studies	   in	  recent	  years	  have	  shown	  that	  CSCs	  are	  closely	  related	  to	  poor	  clinical	  outcomes	  in	  different	  cancers	  162-­‐164.	  In	  breast	  cancer,	  the	  frequency	  of	  BCSCs	  has	  been	   demonstrated	   to	   be	   associated	   with	   the	   aggressiveness	   of	   primary	   breast	  cancer	  165.	   In	  experiments	   involving	  orthotopic	  transplantation	  of	  different	  types	  of	   breast	   cancer	   cells,	   poorly	   differentiated	   tumors	   containing	   higher	   BCSCs	  content	  165,166.	  Another	  batch	  of	  studies	  showed	  that	  triple-­‐negative	  breast	  cancers	  that	  can	  also	  be	  classified	  as	  claudin-­‐low	  subtypes	  have	  a	  much	  worse	  prognosis	  due	  to	  a	  clear	  enrichment	  of	  the	  BCSCs	  signature	  compared	  to	  the	  luminal	  types	  of	  cancer	   167,168.	  Moreover,	   accumulating	   evidence	   supports	   the	   existence	   of	  BCSCs	  leading	  to	  failure	  of	  conventional	  systemic	  therapies	  169-­‐171.	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1.4.5 Major	  pathways	  utilized	  by	  BCSCs	  to	  mediate	  treatment	  resistance	  In	  order	  to	  better	  recognize	  the	  nature	  of	  BCSCs	  and	  effectively	  target	  this	  unique	  cell	   type	   in	   future	   therapies,	   it	   is	   important	   to	   first	  understand	  the	  details	  about	  the	  different	  pathways	  BCSCs	  utilize	   to	  maintain	   their	   self-­‐renewal,	   survival	  and	  slow	  proliferating	  features.	  	  
1.4.5.1 Hedgehog	  signaling	  Hedgehog	  (Hh)	  was	   first	   identified	  during	  Drosophila	  embryonic	  genetic	  pattern	  screening	   172.	   It	   is	   critical	   in	   developing	   embryos	   to	   direct	   organogenesis,	  regulating	  cell	  proliferation	  and	  differentiation.	  Although	  its	  significant	  function	  in	  postnatal	  mammary	   gland	   development	   is	   under	   debate,	   Hh	   signaling	   has	   been	  shown	   to	   play	   an	   important	   role	   in	   normal	   breast	   stem	   cells.	   Paracrine	   Hh	  signaling	   can	   expand	   and	   stimulate	   progenitor	   population	   proliferation	   in	   the	  mouse	   mammary	   gland	   173,174.	   Liu	   et	   al.	   and	   Moraes	   et	   al.	   reported	   that	   Hh	  signaling	  activation	  could	  promote	  mammosphere	  formation	  in	  normal	  mammary	  stem	   cells,	   whereas	   treatment	   with	   its	   inhibitor	   cyclopamine	   can	   reverse	   this	  effect	  175,176.	  	  Giving	   the	   evidence	   from	   above,	   it	   is	   not	   surprising	   to	   find	  Hh	   also	   involved	   in	  malignant	   BCSCs	   in	   the	  mammary	   system.	   Hh	   signaling	  was	   found	   to	   be	   highly	  activated	   within	   the	   subpopulation	   of	   CD44+/CD24-­‐	   cells	   from	   patient-­‐derived	  BCSCs.	   In	   a	  mouse	  model,	   activation	  of	  Hh	   induced	  mammosphere	   formation	   in	  p53-­‐null	  mouse	  mammary	   tumor	   through	   the	   polycomb	  protein	  BMI1,	  which	   is	  usually	   overexpressed	   in	   the	   CD29H/CD24H	   subset	   of	   cells,	   and	   a	   reduction	   of	  BMI1	   expression	   led	   to	   decreased	   mammosphere	   formation175,177.	   Moreover,	  regulators	  in	  the	  Hh	  signaling	  pathway,	  for	  example	  GLI1,	  GLI2	  (GLI	  transcription	  family	  members),	  and	  BMI1	  are	  expressed	  at	  higher	  levels	  in	  CD44+/CD24-­‐	  BCSCs	  compared	   to	   bulk	   tumor	   cells.	   Recently,	   GLI1	   as	   a	   downstream	  mediator	   of	   Hh	  signaling	  has	  been	  shown	  to	  stimulate	  triple-­‐negative	  breast	  cancer	   initiation	  178	  and	  it	  is	  active	  in	  luminal	  breast	  cancers,	  suggesting	  it	  is	  required	  for	  BCSCs	  to	  self-­‐renew	   179.	   These	   results	   indicate	   that	   targeting	  Hh	   signaling	   components	   is	   one	  approach	  to	  disable	  BCSCs.	  	  
1.4.5.2 Notch	  signaling	  In	  mammals,	  there	  are	  four	  transmembrane	  Notch	  receptor	  proteins	  (Notch	  1-­‐4).	  Activation	  of	   the	  Notch	   signaling	  pathway	  occurs	  when	   the	  Notch	   receptors	  1-­‐4	  bind	  with	  their	  ligands	  in	  the	  cells.	  Binding	  leads	  to	  proteolytic	  cleavage	  cascades,	  caused	   by	   internal	   cleavage	   by	   gamma-­‐secretase	   as	   well	   as	   by	   ADAM	  metalloprotease	   family	  members	   180.	  Cleavage	   results	   in	   the	   translocation	  of	   the	  NICD	   (Notch	   intracellular	   domain)	   into	   the	   nucleus	   where	   it	   forms	   a	   trimeric	  complex	  with	  the	  DNA-­‐binding	  protein	  181.	  This	  further	  induces	  the	  expression	  of	  Notch	  downstream	  target	  genes	  including	  Hey,	  cyclin	  D1,	  c-­‐Myc	  and	  Hes	  182.	  	  Notch	  signaling	  in	  breast	  cancer	  was	  demonstrated	  by	  the	  identification	  of	  a	  proto-­‐oncogene	   that	   was	   being	   abnormally	   expressed	   in	   response	   to	   Notch-­‐4	   by	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retroviral	  insertions	  in	  mouse	  mammary	  cancers	  183.	  An	  activated	  Notch	  pathway	  will	  lead	  to	  the	  formation	  of	  mammospheres	  in	  sequential	  passages	  from	  normal	  mammary	   stem	   cells	   while	   specific	   inhibitors	   can	   suppress	   the	   process	   184.	   In	  addition,	   both	   Notch1	   and	   Notch4	   antibodies	   can	   decrease	   the	   mammosphere	  formation	   efficiency	   of	   breast	   cancer	   cells	   from	   patient	   materials	   or	   patient-­‐derived	  xenografts	  (PDX)	  in	  mouse	  models185,186,	  suggesting	  the	  importance	  of	  the	  function	  of	  Notch	   in	  both	  normal	   stem	  cells	   and	  cancer	   stem	  cells	   in	   the	  breast.	  Importantly,	   one	   study	   showed	   Notch4	   activity	   increased	   8-­‐fold	   in	   the	  CD44+/CD24-­‐	  BCSCs	   subpopulation,	   and	   inhibition	  of	  Notch4	   reduced	   the	  BCSCs	  frequency	   in	   breast	   cancer	   cell	   lines	   along	   with	   complete	   inhibition	   of	   tumor	  growth187.	  	  Another	   study	   observed	   activated	   Notch	   signaling	   in	   ER-­‐	   cells,	   although	   it	   is	  inactivated	   in	   ER+	   cells	   even	  when	   estradiol	   is	   present188,	   providing	   a	   potential	  target	  for	  hindering	  Notch	  signaling	  to	  attenuate	  endocrine	  therapy	  resistance	  in	  the	  putative	  BCSCs,	  which	  are	  defined	  as	  having	  an	  ER-­‐	  status.	  From	  a	  more	  recent	  study,	   in	   basal	   like	   breast	   cancer,	  where	   the	   expression	   of	  Notch	   ligand	   JAG1	   is	  induced	  by	  NF-­‐κB,	  Notch	  signaling	   in	  non-­‐tumorigenic	  cancer	  cells	  could	  also	  be	  triggered,	   leading	   to	   the	   expansion	   of	   the	   BCSCs	   population189.	   Notably,	   Notch1	  activity	  was	  shown	  to	  be	  lower	  in	  BCSCs	  compared	  to	  more	  differentiated	  cancer	  cells.	  This	  might	  imply	  that	  different	  Notch	  receptors	  play	  a	  role	  in	  the	  regulation	  of	  CSCs	  and	  other	  cancer	  cells	  in	  the	  breast	  132.	  
1.4.5.3 Cytokine	  and	  IL-­‐8/CXCR1/2	  signaling	  Recognizing	   the	   cytokine	   signaling	  network	   is	   essential	   to	   understanding	   tumor	  biology,	  especially	   in	   cell	   integrations	  within	  a	   tumor	  microenvironment.	  Rather	  than	   simplistically	   viewing	   the	   solid	   breast	   tumor	   as	   a	   sheet	   of	   homogenous	  epithelial	  cells	  cultured	  in	  vitro,	  tumors	  in	  physiological	  conditions	  consist	  more	  of	  a	  hierarchical	  complex	  composed	  not	  only	  of	  epithelial	  cells,	  but	  also	  endothelial	  cells,	   fibroblasts	  and	  other	  cell	   types	   that	  communicate	  with	  each	  other	   through	  growth	  factors	  and	  cytokines.	  Interfering	  with	  this	  network	  is	  a	  growing	  interest	  for	  drug	  discovery,	  because	  disrupting	  this	  network	  seems	  to	  be	  highly	  effective	  at	  completely	  eradicating	  tumors	  in	  acute	  myeloid	  leukemia	  (AML)	  in	  mouse	  models	  190-­‐192.	  Several	  cytokines	  including	  IL-­‐6	  193,	   IL-­‐8	  and	  the	  CXCR1	  receptor	  were	  shown	  to	  be	  involved	  in	  regulating	  BCSCs.	  CXCR1	  belongs	  to	  the	  G-­‐protein-­‐coupled	  receptor	  family.	  Its	  expression	  is	  higher	  in	  ALDH1-­‐positive	  cells	  from	  several	  breast	  cancer	  cell	   lines	   139.	   IL-­‐8	   treatment	   can	   directly	   stimulate	   an	   increase	   in	   the	   ALDH1-­‐positive	  fraction	  and	  mammosphere	  formation	  in	  a	  panel	  of	  breast	  cancer	  cell	  lines	  139,194.	   Ginestier	   and	   colleagues	   demonstrated	   that	   in	   breast	   cancer	   cells,	   the	  proportion	   of	   cells	   that	   are	   CXCR1-­‐positive	   overlaps	   with	   the	   ALDH1-­‐positive	  subpopulation.	   It	   is	   possible	   that	   BCSCs	   could	   be	   depleted	   when	   subjecting	   to	  treatment	  with	  CXCR1	  inhibitors	  195.	  	  As	   the	  most-­‐studied	  CXCR1/2	   ligand,	   IL-­‐8	  has	  been	   reported	   to	  be	  expressed	   in	  response	  to	  signals	  send	  from	  BCSCs,	  and	  mesenchymal	  stem	  cells	  secret	  IL-­‐8	  to	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reinforce	   the	  message	   from	  BCSCs	   33.	   Recent	   publications	   have	   also	   shown	   that	  stimulating	   IL-­‐8/CXCR	   can	   induce	  mammosphere	   formation,	   and	   the	   process	   is	  partially	  mediated	  by	  EGFR/HER2	  signaling	  194.	  Antagonizing	  IL-­‐8/CXCR	  seems	  to	  be	   a	   rational	   strategy	   for	   targeting	   BCSCs,	   and	   clinical	   trials	   using	   antibodies	  against	   IL-­‐8	  have	  shown	  promising	  results	   in	   treating	   inflammatory	  diseases	  196.	  However,	   the	   benefits	   from	   inhibiting	   IL-­‐8	   should	   not	   be	   exaggerated,	   since	  CXCR1/2	  activation	  can	  be	  achieved	  by	  binding	  to	  a	  broad	  range	  of	  other	  ligands	  197.	   Hence,	   when	   developing	   new	   therapeutic	   strategies	   the	   focus	   should	   be	   on	  blocking	  CXCR	  function	   for	  better	  specificity,	  or	  on	  using	  combination	  treatment	  with	  current	  drugs	  that	  provide	  an	  additive	  effect.	  	  
1.4.5.4 AKT	  as	  a	  central	  node	  in	  BCSCs	  signaling	  pathways	  AKT	   is	   a	   central	  mediator	   in	   the	   phosphatidylinositol	   3-­‐kinase	   (PI3K),	  Wnt	   and	  other	  signaling	  pathways	  and	  it	  is	  critical	  in	  regulating	  metabolic	  homeostasis.	  The	  AKT	   pathway	   is	   activated	   by	   binding	   of	   an	   extracellular	   ligand	   to	   a	  receptor	  tyrosine	  kinase	  (RTK)	  in	  the	  plasma	  membrane,	  causing	  phosphorylation	  of	  PI3K,	  which	   leads	   to	   the	   membrane	   interaction	   with	   phosphoinositides	   that	   act	   as	  second	  messengers	  to	  recruit	  and	  fully	  activate	  AKT	  198.	  Phosphorylation	  of	  AKT	  triggers	  downstream	  cascades	  of	  different	  proteins	  that	  regulate	  diverse	  biological	  functions,	   such	   as	   cell	   proliferation,	   survival,	   apoptosis	   and	   mobility	   198.	   The	  components	   of	   AKT	   signaling	   are	   widely	   found	   to	   be	   gain-­‐or-­‐loss	   of	   function	  mutations	   in	   human	   cancers.	   All	   of	   these	   deregulations	   lead	   to	   neoplastic	  transformation	  199.	  PTEN	  is	  a	  lipid	  phosphatase	  that	  is	  upstream	  of	  AKT	  200,	  which	  functions	  as	  a	  tumor	  suppressor	  that	  opposes	  PI3K	  to	  phosphorylate	  AKT	  201,202.	  Loss	  of	  PTEN	  has	  been	  observed	  in	  many	  tumors,	  resulting	  in	  the	  accumulation	  of	  PIP3,	   a	   product	   of	   PI3K,	   that	   can	   be	   dephosphorylated	   by	   PTEN	  which	   leads	   to	  further	   activation	   of	   a	   signaling	   cascade	   such	   as	   AKT,	   mTOR	   and	  phosphatidylinositol	  dependent	  kinases	  200,201.	  Activated	  AKT	  promotes	  cell	  cycle	  progression	   and	   down-­‐regulates	   pro-­‐apoptotic	   factors.	   In	   mouse	  models,	   it	   has	  been	  shown	  that	  the	  PI3K/AKT	  pathway	  can	  mediate	  stem	  cell	  maintenance	  and	  malignant	  transformation	  in	  a	  variety	  of	  tissues	  203-­‐206.	  In	   normal	   mammary	   gland	   stem	   cells	   and	   breast	   cancer,	   the	   role	   of	   PTEN	   is	  documented	   from	   different	   observations.	   In	   mammary	   epithelial	   cells,	   PTEN	  deletion	   induces	   precocious	   development	   and	   neoplasia	   in	   the	  mammary	   gland	  207.	  In	  normal	  breast	  tissue	  from	  humans,	  knockdown	  of	  PTEN	  increases	  activation	  of	  the	  Wnt	  pathway,	  AKT	  activity	  and	  boosts	  formation	  of	  mammospheres	  208.	  In	  different	  breast	  cancer	  cell	  lines,	  PTEN	  knockdown	  again	  increases	  mammosphere	  formation	   and	   drives	   tumor	   initiation	   in	   NOD/SCID	  mice.	   In	   normal	   mammary	  cells,	  knockdown	  of	  PTEN	  induces	  disorganized	  hyperplastic	  lesion	  generation	  in	  mouse	  models	   208.	   Accordingly,	   the	   AKT	   inhibitor	   results	   in	   formation	   of	   fewer	  mammospheres	   in	   vitro	   and	   reduces	   hyperplastic	   lesions,	   tumor	   growth	   and	  formation	  of	  secondary	  tumor	  dramatically	  in	  vivo.	  In	  consequence,	  Wnt	  signaling	  activation	  increases	  mammosphere	  formation	  in	  patient	  derived	  material	  208-­‐210.	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1.4.6 Metabolism	  signaling	  pathways	  Under	  normal	  physiological	  conditions,	  glucose	  is	  the	  primary	  source	  of	  energy	  for	  cellular	  respiration.	  In	  glucose	  metabolism,	  around	  70%	  of	  ATP	  is	  synthesized	  by	  oxidative	   phosphorylation	   and	   the	   remaining	   30%	   is	   by	   glycolysis,	   though	   the	  ratio	   of	   ATP	   generated	   from	   each	   process	   varies	   in	   different	   cell	   types,	   under	  different	  growth	  conditions	  and	  in	  different	  microenvironments	  211.	  In	  most	  solid	  tumors,	  an	  hypoxic	  core	  is	  usually	  found.	  Therefore	  in	  cancer	  cells,	  it	  is	  common	  to	  observe	   a	   metabolic	   switch	   towards	   enhanced	   glycolysis	   over	   respiration	   in	  defiance	   of	   functional	   oxidative	   phosphorylation	   212.	  Meanwhile,	   if	   the	   oxidative	  phosphorylation	   machinery	   is	   restricted	   by	   suppression	   of	   mitochondrial	  respiration	   or	   hypoxia,	   lactate	   fermentation	   is	   recruited	   to	   compensate	   for	   the	  cellular	  energy	  generation	  213.	  	  Cancer	  cells	  require	  an	  enormous	  amount	  of	  energy	  in	  order	  to	  rapidly	  proliferate.	  The	   altered	  metabolism	   during	   tumor	   progression	   that	   cancer	   cells	  manifest	   to	  meet	   energy	   needs	   is	   called	   the	   Warburg	   effect	   214.	   The	   process	   involves	   a	  metabolic	   shift	   from	  oxidative	   respiration	   to	   glycolysis	   and	   lactate	   fermentation	  even	  with	  the	  presence	  of	  oxygen,	  and	  it	  was	  originally	  interpreted	  as	  an	  increased	  glycolysis	  to	  meet	  energy	  demand	  in	  tumors	  as	  a	  result	  of	  mitochondrial	  defects	  with	   disrupted	   mitochondrial	   respirations.	   However,	   hypoxia	   can	   diminish	   the	  glycolytic	  pathway	  inhibited	  by	  oxygen	  and	  further	  enhance	  anaerobic	  glycolysis	  in	  cancer	  cells	  212.	  	  	  However,	  it	  was	  later	  discovered	  that	  cancer	  cells	  can	  utilize	  glycolysis	  for	  energy	  demand	   even	   with	   normally	   functioning	   mitochondria.	   Due	   to	   the	   much	   lower	  efficiency	   of	   converting	   glucose	   to	   lactate	   as	   compared	   to	   directly	  metabolizing	  glucose	   through	   the	   mitochondrial	   oxidative	   phosphorylation,	   a	   high	   rate	   of	  glucose	   uptake	   is	   necessary	   to	   provide	   the	   increased	   energy	   consumption	   to	  support	   rapid	   cell	   proliferation.	   ATP	   generation	   depending	   on	   fermentative	  metabolism	   is	   a	   long	   term	   reprogramming	   process	   in	   cancer	   cells.	   In	   addition,	  acute	   repressive	   signaling	   cascades	   suppressing	  mitochondrial	   function	   are	   also	  commonly	  observed	  211-­‐213.	  Compared	  to	  normal	  cells,	  this	  metabolic	  shift	  towards	  glycolysis	  and	  suppression	  of	  mitochondrial	  respiratory	  machinery	  is	  irreversible,	  and	   alterations	   of	   glucose	   metabolism	   supplying	   additional	   energy	   to	   support	  tumor	  growth	  have	  been	  reported	  in	  many	  studies.	  This	  suggests	  that	  inhibition	  of	  glycolysis	   could	   lead	   to	   reduced	   tumor	   cell	   proliferation	   and	   prevent	   tumor	  progression	  215.	  	  In	  humans,	  normal	  embryonic	  stem	  cells	  display	  a	  glycolytic	  metabolism,	  possibly	  due	   to	   a	  mitochondria	   variation.	  Based	  on	   some	   studies,	   highly	  undifferentiated	  cells	  such	  as	  CSCs	  are	  able	  to	  shift	  between	  glutaminolysis	  and	  aerobic	  glycolysis	  216,217.	   Feng	   and	   colleagues	   recently	   showed	   that	   enriched	  populations	   of	   BCSCs	  rely	  more	  on	  glycolysis	   than	  do	  non-­‐tumorigenic	   cells,	  based	  on	  observations	  of	  mitochondrial	   number	   differences	   and	   repressed	   expression	   of	   the	   key	  mitochondrial	  enzymes	  218.	  The	  glycolytic	  phenotype	  is	  distinctive	  in	  CSCs	  with	  an	  overexpression	  of	  most	  of	  the	  glycolytic	  enzymes.	  Lactate	  dehydrogenase	  and	  its	  isoforms	   are	   found	   to	   be	   highly	   expressed	   under	   normal	   conditions,	   and	   are	  
19 
upregulated	   under	   c-­‐MYC	   activation	   and	   hypoxia,	   which	   facilitate	  moving	   away	  from	  oxidative	  metabolism	  219.	  	  However,	  there	  are	  still	  some	  cancer	  cells	  that	  rely	  on	  oxidative	  phosphorylation	  rather	   than	   glycolysis.	   These	   different	  metabolic	   profiles	   exhibited	   by	   CSCs	   are	  dependent	  on	  their	  degree	  of	  differentiation	  and	  tissue	  of	  origin	  219.	  Liver	  cancer	  cells,	   for	   example,	   are	   usually	   highly	   undifferentiated	   and	   tend	   to	   rely	  more	   on	  glycolysis	  than	  differentiated	  tumor	  cells	  220.	  Normal	  glioma	  stem	  cells	  have	  been	  shown	  to	  consume	  less	  glucose	  and	  yield	  less	  lactate	  than	  their	  related	  cancerous	  cells	  221.	  Zhang	  et	  al.	  showed	  that	  non-­‐small	  cell	  lung	  cancer	  stem	  cells	  selectively	  upregulate	   glycolytic	   genes	   222.	   Despite	   the	   intrinsic	   needs	   of	   CSCs,	   exogenous	  factors	  also	  influence	  both	  metabolic	  processes	  and	  cell	  fate	  219.	  	  The	  concept	  of	  niche,	  or	  the	  resident	  microenvironment,	  is	  an	  essential	  factor	  that	  distinguishes	   CSCs	   from	   normal	   stem	   cells.	   Niche	   functions	   as	   a	   source	   of	  molecules,	   which	   either	   activate	   or	   inhibit	   signaling	   transactions.	   In	   normal	  tissues,	   the	   microenvironment	   for	   stem	   cells	   is	   known	   to	   retain	   the	   balance	  between	  self-­‐renewal,	  proliferation	  and	  differentiation	  223-­‐225,	  whereas	  in	  CSCs,	  the	  required	   tumor	   microenvironment	   is	   altered	   towards	   maintaining	   the	  proliferating	  signals	  226,227.	  	  The	  idea	  that	  tumor	  microenvironment	  plays	  a	  central	  role	  in	  tumor	  initiation	  and	  progression	  has	  been	  widely	   accepted.	  Alterations	   in	   the	  microenvironment	   can	  be	   achieved	   through	   stromal	   or	   immune	   cells,	   alternation	   of	   extracellular	  modifications,	   as	  well	   as	   changes	   in	   the	   oxygen	   concentration	   228.	   Typically,	   the	  tumor	   niches	   are	   characterized	   as	   having	   low	   oxygen	   concentrations	   and	   a	  glycolytic-­‐mediated	  phenotype,	  which	   is	  partially	  promoted	  by	   the	  HIF-­‐signaling	  pathway.	  During	  the	  cancer	  initiation	  phase,	  the	  niche	  becomes	  hypoxic	  and	  favors	  the	   activation	   of	   genes	   associated	   with	   stem-­‐cell-­‐like	   profiles,	   such	   as	   Notch,	  
Nanog,	  Sox2	  or	  Oct4,	  together	  with	  genes	  associated	  with	  the	  glycolytic	  switch	  229.	  	  In	  solid	  tumors,	  the	  capacity	  of	  CSCs	  to	  modulate	  the	  tumor	  microenvironment	  has	  led	  to	  the	  proposal	  that	  CSCs	  adaptation	  to	  hypoxia	  may	  lead	  to	  the	  glycolytic	  shift	  and	  finally	  induce	  acidity	  changes	  in	  tumor	  niches.	  In	  brain	  tumor	  models,	  local	  pH	  measurements	  shift	  from	  7.1	  to	  6.8	  in	  normal	  tissue	  versus	  tumor	  tissue	  230.	  The	  acidification	   of	   the	   microenvironment	   would	   in	   turn	   modify	   the	   acidity	   of	  proteases,	   which	   modulate	   extracellular	   matrix	   degradation.	   These	   changes	   of	  acidification	  promote	  maintenance	  of	   the	  CSCs	  phenotype	  maintenance	   in	  bulky	  tumors.	   Several	   studies	   have	   also	   suggested	   that	   through	   activation	   of	   enzymes	  involved	  in	  the	  extracellular	  matrix	  231	  and	  HIF-­‐dependent	  pathways,	  hypoxia	  can	  promote	   and	   facilitate	   metastasis	   of	   cancer	   232.	   In	   clinic	   practice,	   there	   is	   an	  association	   between	   the	   presence	   of	   a	   hypoxia	   core	   in	   tumors	   and	   a	   poor	  prognosis	  for	  patients	  232-­‐234.	  
1.5 MODELING	  BREAST	  CANCER	  Breast	   cancer	   is	   not	   a	   single	   disease.	   Instead,	   it	   is	   a	  mixture	   of	   breast	   diseases	  having	  diverse	  genetic	  variations,	  histopathological	  profiles	  and	  clinical	  outcomes.	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For	  many	  decades,	  our	  knowledge	  and	  understanding	  of	  breast	  cancer	  biology	  has	  been	   based	   on	   experimental	  model	   systems.	   A	  major	   question	   that	   needs	   to	   be	  considered	  is	  whether	  the	  experimental	  models	  really	  recapitulate	  the	  true	  forms	  of	  breast	  cancer.	  Due	  to	  its	  heterogeneity	  and	  complexity,	  no	  single	  model	  would	  be	  able	  to	  completely	  represent	  or	  mimic	  all	  aspects	  of	  breast	  cancer.	  Thus,	  when	  modeling	   breast	   cancer	   to	   investigate	   clinical	   consequences,	   we	   should	   always	  keep	  in	  mind	  key	  questions	  such	  as	  how	  to	  choose	  the	  current	  existing	  model	  and	  how	  to	  improve	  preclinical	  models	  based	  on	  the	  research	  question.	  It	  is	  necessary	  to	  develop	  new	  models	   for	   treatment	   evaluation	   in	   terms	  of	  metastasis	   and	   the	  mechanisms	   underlying	   secondary	   tumor	   progression,	   which	   is	   the	   principal	  cause	  of	  mortality	  of	  breast	  cancer.	  	  
1.5.1 In	  vitro	  breast	  cancer	  cell	  line	  versus	  primary	  human	  breast	  cancer	  
cells	  Recently,	   several	   studies	   have	   investigated	   gene	   genomic	   alterations	   and	  expression	   profiles	   by	   comparing	   primary	   breast	   cancers	   and	   various	   breast	  cancer	  cell	  lines	  10,235-­‐237.	  Not	  surprisingly,	  the	  findings	  from	  these	  studies	  indicate	  that	   none	   of	   these	   cell	   lines	   alone	   is	   representative	   of	   breast	   cancer.	   However,	  using	  a	  panel	  of	   cells	   lines	  can	  represent	   the	  heterogeneity	  observed	   in	  primary	  breast	   cancers.	   A	   comprehensive	   study	   conducted	   by	   Neve	   et	   al.	   reported	   that	  many	  genomic	   abnormalities	   are	   the	   same	  between	  a	  panel	   of	  51	  breast	   cancer	  cell	   lines	   and	   primary	   tumors	   237.	   Therefore,	   the	   establishment	   of	   cultured	   cell	  lines	   to	   model	   primary	   breast	   cancer	   can	   be	   adapted	   to	   study	   the	   common	  genomic	  aberrations.	  	  Nevertheless,	   the	   differences	   between	   the	   cell	   lines	   compared	   to	   the	   primary	  tumors	   are	   still	   crucial	   for	   potential	   usage.	   For	   instance,	   not	   all	   of	   the	   common	  subtypes	   of	   breast	   carcinoma	   are	   represented,	   including	   luminal	   A,	   luminal	   B,	  HER2	   enriched,	   triple	   negative	   and	   basal	   like	   subtypes.	   Additionally,	   the	  frequencies	  of	  copy	  number	  abnormalities	  differ	  profoundly	  between	  luminal	  and	  basal	  subtypes	  of	  primary	  tumors.	  Notably,	  cell	  lines	  fail	  to	  display	  the	  features	  of	  the	   luminal	  subtypes	  238.	  Thus,	  although	   investigators	  prefer	   to	  classify	  cell	   lines	  into	   luminal	   and	   basal	   subtypes,	   this	   is	   less-­‐than-­‐accurately	   representative	   of	  breast	   cancer	   biology	   in	   the	   clinic.	   This	   suggests	   that	   caution	   needs	   to	   be	   used	  when	  using	  the	  cell	  line	  model	  to	  study	  breast	  cancer.	  	  The	   reason	  why	   a	   difference	   exists	   between	   cell	   lines	   and	   primary	   tumors	   can	  probably	   be	   explained	   by	   the	   methods	   used	   to	   generate	   cell	   lines	   from	   breast	  cancer	  patients.	  They	  are	  usually	  obtained	  either	   from	  pleural	  effusions	  or	   from	  advanced	   stage	   tumors,	   therefore	   the	   most	   malignant	   variants	   that	   could	   be	  adapted	  to	  cell	  culture	  represent	   the	  cell	   lines.	  Notably,	  gene	  expression	  profiles	  have	   shown	   that	   primary	   tumors	   and	   secondary	   tumors	   from	  metastasis	   share	  high	  similarities	  239,240.	  This	  suggests	  the	  possibility	  of	  establishing	  new	  cell	   lines	  from	   primary	   tumors	   at	   different	   stages,	   by	   using	   the	   applications	   of	   gene	  expression	  profiling	  and	  improved	  methods	  for	  culturing	  primary	  cells.	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Nowadays,	  the	  BCSCs	  hypothesis	  has	  attracted	  a	  lot	  of	  attention	  due	  to	  its	  unique	  properties	   and	   possible	   prognostic	   applications.	   Thus,	   it	   is	   essential	   to	   ask	  whether	  breast	  cancer	  cell	   lines	  contain	  any	  BCSCs	  subpopulations.	  So	   far,	   some	  laboratories	  have	  reported	   that	   they	  have	  successfully	   identified	  subsets	  of	   cells	  having	  distinct	  tumor	  initiating	  phenotypes	  within	  various	  cell	   lines162,241-­‐243.	  For	  instance,	   MCF-­‐7	   is	   enriched	   in	   the	   subpopulation	   of	   cells	   able	   to	   form	  mammospheres,	   exhibiting	   the	   surface	   marker	   CD44+/CD24-­‐	   profile,	   which	   is	  1000	   times	  more	   capable	  of	   initiating	   tumors	   in	  mice	   compared	   to	   the	  parental	  cells	  244.	  Kuperwasser	  and	  colleagues	  performed	  in	  vivo	  limiting	  dilution	  transplantation	  to	  test	  the	  tumorigenic	  capability	  of	  CD44+/CD24-­‐	  subpopulations	  from	  breast	  cancer	  cell	  lines.	  They	  noticed	  these	  markers	  did	  not	  correlate	  with	  tumor	  initiation	  and	  instead	   indicated	   a	   basal-­‐like	   subtype.	   However,	   when	   incorporating	   the	   ESA+	  fraction	  together	  with	  the	  CD44+/CD24-­‐	  cells,	  tumorigenic	  capability	  of	  the	  subset	  increased	  245.	  Accumulating	   evidence	   demonstrates	   that	   the	   CD44+/CD24-­‐/ESA+	   phenotype	  varies	   within	   both	   cell	   lines	   and	   breast	   cancers,	   suggesting	   that	   the	   utility	   of	  surface	   markers	   is	   not	   as	   broadly	   indicative	   as	   expected	   for	   tumor	   initiating	  capacity	  141,246,247.	  Besides,	  the	  correlation	  of	  surface	  marker	  phenotypes	  to	  clinical	  outcomes	  has	  not	  yet	  been	  established	  141,246,248.	  Thus,	  more	  systematic	  functional	  studies	   are	   needed.	   In	   the	   meantime,	   utilizing	   different	   cell	   lines	   to	   represent	  breast	   cancer	   subtypes	   is	   also	   necessary	   to	   provide	   solid	   conclusions	   about	   the	  CSCs	   compartment	   in	   each	   cell	   line,	   and	  whether	   they	   display	   identical	   surface	  markers	   for	   further	   identification.	   Despite	   their	   limitations,	   there	   are	   several	  studies	  suggesting	  that	  certain	  breast	  cancer	  cell	   lines	  can	  be	  used	  to	  investigate	  the	   differences	   of	   cellular	   and	  molecular	   components	   between	   tumorigenic	   and	  non-­‐tumorigenic	  subpopulations	  162,244,249.	  	  	  	  	  
1.5.2 In	  vivo	  models	  The	  orthotropic	  transplantation	  of	  breast	  cancer	  cell	   lines	   into	  xenografts	  allows	  the	  investigation	  of	  tumor	  growth	  in	  vivo,	  by	  which	  the	  complex	  tumor	  stromal	  cell	  interaction	   and	   microenvironments	   that	   facilitate	   tumor	   initiation	   and	  progression	  can	  be	  taken	  into	  consideration.	  Using	  xenografts	  has	  become	  a	  gold	  standard	  model	   to	   study	   the	   facts	  of	  breast	   cancer	  biology,	   including	   the	   role	  of	  tumor	   extracellular	   matrix	   interactions,	   angiogenesis,	   inflammation,	   the	   genetic	  alterations	   that	   contribute	   to	   tumor	   formation	   and	   growth,	   and	   even	   the	  transformations	  that	  lead	  to	  stepwise	  metastasis	  250.	  However,	  there	  are	  still	  some	  aspects	  that	  need	  to	  be	  carefully	  considered	  when	  using	  xenograft	  models.	  A	  crucial	  limitation	  of	  this	  model	  is	  that	  using	  cell	  lines	  to	  reform	  tumors	  is	  unable	  to	   represent	   all	   five	   common	   subtypes	   of	   breast	   cancer	   and	   their	   intrinsic	  heterogeneity	  as	  observed	  in	  vivo.	  Technical	  aspects	  that	  can	  influence	  the	  utility	  of	  xenografts	  should	  be	  mentioned	  as	  well.	  First	  of	  all,	  xenografts	  to	  model	  breast	  cancer	   have	   always	   been	   established	   in	   immunodeficient	   mice	   without	   intact	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immune	   systems,	   which	   might	   profoundly	   affect	   tumor	   development	   and	  progression	  251.	  Many	  studies	  have	  shown	  that	  immune	  system	  interactions	  in	  the	  early	  stages	  of	  tumor	  formation	  and	  later	  in	  metastasis	  play	  an	  important	  role	  in	  breast	   cancer	   252,253.	   In	   addition,	   the	   tumor	   cells	   are	   frequently	   placed	   into	   the	  flank	  of	  mice	  by	  subcutaneous	  injection	  and	  it	  is	  not	  difficult	  to	  conclude	  that	  this	  microenvironment	  is	  very	  different	  from	  the	  real	  intratumoral	  microenvironment	  and	  thus	  alters	  the	  growth	  potential	  of	  engrafted	  cells.	  Orthotropic	  transplantation	  into	  the	  mammary	  gland	  might	  be	  more	  favorable,	  yet	  there	  are	  huge	  differences	  between	   human	   and	   mouse	   mammary	   stroma.	   Alternatively,	   introduction	   of	  tumor	  cells	  into	  the	  mammary	  fat	  pad	  is	  also	  widely	  used,	  although	  the	  epithelial	  and	   stromal	   component	   interactions	   cannot	   be	   represented	   in	   the	   mouse	  mammary	   fat	   pad	   254.	   Using	   mouse	   models	   to	   investigate	   metastasis	   also	   has	  limitations.	  In	  mice,	  metastatic	  cells	  usually	  fail	  to	  grow	  at	  other	  distant	  sites	  but	  prefer	   to	   colonize	   the	   lungs,	  which	   does	   not	   represent	   the	   situation	   in	   humans,	  where	  metastasis	  most	  often	  occurs	  in	  the	  lymph	  nodes,	  liver,	  bone	  and	  brain	  255.	  	  	  However,	  modeling	  breast	  cancer	   in	  xenografts	   is	   still	   relevant	   to	  human	  cancer	  prognosis.	  In	  a	  recent	  and	  elegant	  study,	  the	  breast	  cancer	  cell	  line	  MDA-­‐MB-­‐231	  was	  used	  by	   intravenous	   injection	   to	   select	   for	  metastatic	   variants	   to	   the	   lungs.	  Molecular	  profiling	  was	  performed	  to	  generate	  a	  metastatic	  gene	  signature	   from	  the	  lung	  metastatic	  variants.	  Interestingly,	  this	  defined	  gene	  signature	  significantly	  correlated	   with	   specifically	   distinguished	   patients	   who	   relapsed	   with	   lung	  metastases	   and	   decreased	   metastasis-­‐free	   survival	   256.	   Other	   studies	   have	   also	  identified	   gene	   signatures	   from	   xenografts	   that	   are	   associated	   with	   distinct	  outcomes	   257,258.	   These	   inspiring	   studies	   demonstrated	   the	   utilities	   of	   xenograft	  models	  and	  their	  relevance	  to	  breast	  cancer	  in	  humans.	  	  In	  recent	  years,	   the	  development	  of	  patient-­‐derived	  xenograft	   (PDX)	  models	  has	  provided	   a	   unique	   tool	   to	   investigate	   breast	   cancer	   biology	   in	   a	  more	   clinically	  oriented	  context.	  These	  xenografts	  can	  be	  generated	  from	  a	  wide	  range	  of	  human	  cancers	   and	   able	   to	   preserve	   inter-­‐	   and	   intra-­‐	   tumor	   heterogeneity	   259.	   Usually,	  fragments	   of	   human	   tumors	   are	   directly	   implanted	   into	   immunocompromised	  mice.	  Therefore,	  the	  regrown	  tumors	  often	  retain	  the	  histological	  characteristics	  of	  the	   parental	   tumors.	   Numerous	   studies	   have	   shown	   PDX	  models	   even	   preserve	  mutation	   profiles	   as	   well	   as	   maintain	   similar	   response	   patterns	   to	   different	  therapies259-­‐262.	   Some	   PDX	   models	   are	   also	   useful	   for	   evaluation	   of	   post-­‐therapeutic	   tumor	   characteristics.	   PDX	   models	   also	   allow	   for	   the	   interactions	  between	   tumor	   cells	   and	   stromal	   compartments	   that	   are	   structured	   in	   human	  cancers	   263.	   However,	   those	   studies	   were	   only	   able	   to	   describe	   results	   from	   a	  limited	  amount	  of	  samples	  and	  subtypes	  because	  the	  transplantation	  efficiencies	  are	  reported	  to	  be	  low.	  
1.5.3 Ex	  vivo	  models	  Representing	  breast	  cancer	  diversity	   is	  an	  issue	  that	  should	  be	  considered	  when	  choosing	  model	  systems.	  The	  heterogeneity	  usually	  cannot	  be	  easily	  or	  accurately	  replicated	  in	  routine	  cancer	  cell	  lines	  or	  xenograft	  models	  as	  previously	  discussed.	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The	   former	  models	   lack	   tumor	   complexity,	   while	   the	   latter	  models	   often	   suffer	  from	   inadequate	   human	   mammary	   gland	   and	   physiological	   environments.	  Alternatively,	  organotypic	  tissue	  slice	  culture	  offers	  an	  attractive	  ex	  vivo	  model,	  as	  not	  only	  can	  it	  preserve	  inter-­‐	  and	  intra-­‐	  tumor	  heterogeneity,	  but	  also	  allows	  for	  evaluation	  of	  drug	   response	  directly	   in	   the	   culture	  and	   subsequent	  downstream	  analysis	   264-­‐266.	   In	   breast	   cancer,	   the	   evaluations	   of	   this	   humanized	  model	   have	  been	  proven	  to	  reflect	   the	  morphological	  and	  histopathological	  properties	  of	   the	  parental	  tumors	  267.	  Careful	  technique	  allows	  for	  culturing	  tissue	  slices	  for	  up	  to	  7	  days,	  although	  downstream	  processing	  is	  somewhat	  challenging	  268.	  Some	  studies	  have	   assessed	   the	   synergistic	   effects	   of	   compounds	   with	   potential	   anti-­‐cancer	  effects	   with	   this	   model,	   indicating	   that	   organotypic	   culture	   can	   respond	   to	  different	  magnitudes	  of	  treatment.	  These	  findings	  further	  reflect	  the	  importance	  of	  taking	  tumor	  heterogeneity	  into	  consideration	  when	  modeling	  breast	  cancer	  269.	  	  Overall,	  the	  ex	  vivo	  model	  has	  advantages	  in	  conducting	  a	  large	  number	  of	  assays	  that	   can	   capture	   many	   aspects	   of	   tumor	   diversity,	   including	   cell	   matrix	  components,	   inter-­‐	   and	   extracellular	   interactions,	   and	   the	   most	   important	  metabolic	  capacities.	   It	  also	  provides	   the	  possibility	   to	  study	  different	  aspects	  of	  cancers.	   It	   could	   also	   contribute	   to	   a	   decrease	   in	   the	   number	   of	   experimental	  animals	   consumed	   in	   cancer	   research.	  More	   studies	   should	   be	   performed	   using	  this	  model.	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2 AIMS	  OF	  THE	  THESIS	  The	  aim	  of	   this	   thesis	   is	   to	   further	  explore	   the	  properties	  of	  breast	   cancer	   stem	  cells	  and	  to	  better	  characterize	  this	  subpopulation.	  We	  also	  aim	  to	  highlight	  their	  importance	   in	   association	   with	   clinical	   outcomes,	   and	   therefore	   they	   may	   be	  helpful	  in	  developing	  targeted	  therapies	  for	  future	  clinical	  use.	  Finally,	  we	  aim	  to	  establish	   a	   better	   system	   to	   preserve	   and	   expand	   primary	   cultures	   from	   breast	  cancer	  specimens	  in	  order	  to	  benefit	  future	  research.	  
Paper	   I:	   to	   identify	   the	   role	   of	   ERβ	   as	   a	   mediator	   of	   estrogen	   action	   and	   the	  possibility	  of	  using	  it	  as	  a	  novel	  target	  for	  endocrine	  therapy	  in	  BCSCs.	  	  
Paper	   II:	   to	   investigate	   the	   reversibility	   of	   BCSCs	   dedifferentiation	   from	   bulk	  tumor	   cells	   and	   to	   explore	  whether	   putative	   BCSCs	   display	   tumorigenicity	   as	   a	  certain	  genotype	  within	  tumors.	  	  
Paper	  III:	  to	  explore	  the	  effect	  of	  tamoxifen	  on	  the	  patient-­‐derived	  BCSCs,	  and	  to	  understand	   the	   potential	   mechanism	   of	   BCSCs-­‐induced	   endocrine	   resistance	   in	  breast	  cancer.	  
Paper	   IV:	   to	   establish	   a	   simple	   and	   standardized	  method	   to	   generate	   material	  from	  small	  breast	  tumors	  without	  risking	  the	  histopathological	  examination,	  and	  to	  isolate	  and	  expand	  cancer	  stem	  cells	  from	  the	  majority	  of	  tumors	  collected	  for	  research	  purposes,	  biobanking,	  and	  next-­‐generation	  sequencing.	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3 MATERIALS AND METHODS The	   unique	   and	  major	  methods	   employed	   in	   this	   thesis	   to	   generate	   results	   are	  described	  below.	  
3.1 IN	  VIVO	  MODELS	  
3.1.1 Uppsala	  cohort	  The	  Uppsala	  breast	  cancer	  cohort	  was	   first	  described	   in	  2005.	   It	  consists	  of	  315	  breast	   cancer	   patients	  who	   had	   been	   diagnosed	   from	   1987	   to	   1989	   in	   Uppsala	  County	   in	   Sweden.	   It	   included	   65%	  of	   all	   breast	   cancer	   patients	   at	   that	   time	   in	  Uppsala.	  The	  clinical	  reports	  and	  histopathological	  characteristics	  were	  retrieved	  from	  the	  patients’	  records.	  Long-­‐term	  patient	  follow-­‐up	  performed	  by	  examining	  the	  survival	  status	  and	  the	  cause	  of	  death	  has	  been	  conducted	  several	  times	  using	  the	   registries.	   Global	   gene	   expression	   analysis	   was	   performed	   on	   260	   of	   the	  patients	   with	   Affymetrix	   microarray	   chips.	   An	   intrinsic	   subtype	   analysis	   was	  performed	   to	   classify	   the	   patients.	   Tissue	   Microarrays	   (TMAs)	   have	   also	   been	  constructed	   from	   the	   original	   formalin	   fixed	   paraffin	   embedded	   tumor	   tissues,	  which	  were	  used	   to	   test	   for	  ERβ	  status	  and	  cancer	   stem	  cell	   surface	  markers	   in	  paper	  I.	  
3.1.2 Mouse	  tumor	  model	  The	   experimental	   tumor	  models	   in	   laboratory	   animals	   included	   the	   orthotropic	  model,	  the	  transplant	  model,	  and	  the	  spontaneous	  model.	  The	  advantages	  of	  using	  mouse	   models	   to	   study	   human	   cancer	   biology	   have	   been	   discussed	   in	   the	  Introduction.	   In	   our	   projects,	   cell	   pellets	   from	   different	   breast	   cancer	   cell	   lines	  were	  orthotropically	  transplanted	  into	  the	  4th	  pair	  of	  mammary	  fat	  pads	  for	  tumor	  initiation	   and	   out-­‐growth.	   Treatments	   were	   administrated	   by	   subcutanenous	  injection	  according	  to	  the	  experimental	  purposes.	  When	  tumor	  growth	  was	  larger	  than	   3	   cm	   in	   diameter,	   the	   mice	   were	   euthanatized	   using	   a	   CO2	   chamber.	   The	  extracted	  tumors	  were	  collected	  for	  subsequential	  validation.	  	  
3.1.3 Mouse	  surgical	  applications	  According	  to	  the	  object	  of	  each	  animal	  experiment,	  mice	  were	  subjected	  to	  certain	  surgical	   procedures	   to	   create	   physiological	   relevant	   models	   and	   to	   mimic	   the	  cancer	  environment	  in	  humans.	  In	  our	  projects,	  when	  studying	  ERα	  agonizing	  and	  antagonizing	  molecules,	   or	   specifically	   focusing	   on	   ERβ	   funtions,	   the	  mice	  were	  ovariectomized	  to	  diminish	  the	  interference	  from	  endogenous	  estrogens.	  In	  other	  cases,	   the	   mammary	   gland	   was	   removed	   from	   the	   mice	   at	   a	   young	   age	   before	  transplanting	   cancer	   cells	   into	   the	   cleared	  mammary	   fat	   pad.	   This	  was	   done	   in	  order	   to	  prevent	   the	  potential	  mammary	  ductal	   tree’s	   extension	   throughout	   the	  mammary	  fat	  pad	  and	  therefore	  disturb	  exotic	  cell	  growth.	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3.2 IN	  VITRO	  MODELS	  
3.2.1 Immunofluorescent	  staining	  Immunofluorescence	   was	   intensively	   utilized	   in	   our	   projects	   to	   identify	   the	  properties	   of	   mammospheres	   from	   clinical	   material.	   This	   microscope-­‐based	  technique	  enabled	  the	  characterization	  of	  cancer	  stem	  cells	  based	  on	  their	  surface	  marker	   status	   such	   as	   CD44,	   CD24	   and	   ALDH1.	   In	   our	   experimental	   settings,	  limited	   access	   to	   clinical	   breast	   cancer	   specimens	   increased	   the	   difficulties	   in	  handling	   such	   delicate	   material.	   Therefore,	   we	   set	   up	   a	   panel	   of	   stable	   and	  repeatable	  immuno-­‐fluorescent	  staining	  techniques	  to	  study	  cancer	  stem	  cells	  and	  their	  functions	  when	  responding	  to	  various	  conditions.	  Small	  amounts	  of	  spheres	  were	   cytospun	   onto	   slides	   and	   incubated	   with	   the	   antibodies	   of	   interest.	   After	  signal	   amplification	   by	   secondary	   antibodies,	   we	   were	   able	   to	   observe	   protein	  expression	   levels	   and	   interactions	   between	   proteins	   under	   the	  microscope.	  We	  believe	  this	  is	  a	  very	  sensitive	  technique	  in	  terms	  of	  its	  implementation	  in	  cancer	  stem	  cell	  research.	  It	  is	  worth	  noting	  that	  choosing	  validated	  primary	  antibodies	  is	  essential	  and	  critical	  for	  generating	  reliable	  results.	  	  
3.2.2 Mammosphere	  formation	  assay	  The	  mammosphere	   formation	   assays	   have	   been	  widely	   used	   for	   their	   ability	   to	  identify	   cancer	   stem	   cells	   based	   on	   their	   self-­‐renewal,	   differentiating	   and	   slow	  proliferating	  capacity	  at	   the	  single	  cell	   level	   in	  vitro.	  We	  mainly	  used	   the	  sphere	  formation	  assay	  to	  detect	   the	  potential	  effect	  of	  molecules	   in	  targeting	   identified	  BCSCs	  when	   stimulating	   or	   inhibiting	   different	   subcellular	   compartments	   in	   the	  cells.	   In	   general,	   spheres	   derived	   from	  either	   patient	  material	   or	   cell	   lines	  were	  trypsinized	   into	   single	   cells	   and	   re-­‐seeded	   into	   culture	   plates,	   then	   they	   were	  incubated	  with	  a	  series	  of	  treatments	  over	  a	  certain	  time,	  to	  observe	  the	  changes	  in	  the	  newly	  formed	  sphere	  number.	  	  
3.3 EX	  VIVO	  MODEL	  AND	  SUPERFICIAL	  SCRAPING	  TECHNIQUE	  
3.3.1 Primary	  breast	  cancer	  cell	  culture	  The	  advantages	  of	  using	  primary	  cultures	  derived	  from	  breast	  cancer	  specimens	  over	  traditional	  cell	  lines	  have	  been	  extensively	  discussed	  in	  the	  introduction.	  The	  major	   obstacle	   in	   long-­‐term	   culturing	   of	   primary	   cells	   is	   how	   to	   maintain	   the	  phenotype	   and	   limit	   genomic	   changes	   compared	   to	   parental	   tumors	   once	  extracted	   outside	   physiological	   conditions.	   We	   therefore	   mainly	   used	   first-­‐generation	  mammospheres	  purified	  from	  patient	  material	  in	  all	  of	  the	  projects	  to	  limit	   genetic	   and	   phenotypic	   changes	   introduced	   during	   the	   culture.	   To	   select	  target	  cancer	  stem	  cell	  populations,	  we	  used	  restricted	  medium	  as	  reported	  in	  the	  thesis	  paper	  IV,	  to	  which	  normal	  serum	  was	  not	  added.	  By	  doing	  so,	  cells	  were	  not	  able	  to	  attach	  and	  undergo	  differentiation	  but	  instead	  displayed	  self-­‐renewal	  and	  a	  slow	  proliferating	  capacity.	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3.3.2 Biobanking	  superficial	  scrapings	  from	  breast	  tumors	  In	  this	  thesis,	   the	  establishment	  of	  the	  superficial	  scraping	  technique	  is	  a	  unique	  technique	  that	  is	  important	  for	  future	  research	  and	  clinical	  purposes.	  A	  sterilized	  scalpel	  was	  scraped	  against	  the	  surface	  of	  the	  resected	  breast	  tumor	  several	  times	  by	  a	   trained	  pathologist.	  The	  cell	   scrapings	  were	   immediately	   transferred	  either	  into	  a	  cryopreservation	  vial	  for	  biobanking	  or	  into	  selective	  medium	  for	  culturing	  (Figure	  3).	  This	  method	  was	  validated	  to	  provide	  sufficient	  material	  for	  later	  gene	  expression	  profiling,	  next	  generation	  sequencing	  analysis	  and	  ex	  vivo	  cell	  models.	  	  	  
Figure	  3.	  The	  flow	  chart	  illustrates	  the	  process	  and	  procedures	  devised	  to	  evaluate	  the	  feasibility	  of	  biobanking	  the	  superficial	  scrapings	  and	  as	  a	  resource	  of	  cancer	  stem-­‐like	  cells.	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4 RESULTS	  AND	  DISCUSSION	  
4.1 PAPER	  I	  
Estrogen	   receptor	   β	   governs	   proliferation	   of	   breast	   cancer	   stem	   cells	   and	   can	   be	  
targeted	  by	  endocrine	  therapy	  	  Breast	  cancer	  stem	  cells	  (BCSCs)	  are	  highly	  tumorigenic	  cells	  expressing	  classical	  embryonic	  stem	  cell	  genes	  such	  as	  NANOG,	  SOX2	  and	  OCT4,	  with	  a	  capacity	  to	  self-­‐renew	  and	  further	  differentiate	  into	  a	  heterogeneous	  tumor	  mass.	  These	  cells	  are	  defined	  by	   their	  potential	   in	   growing	   as	  non-­‐adherent	   spheres	   in	   vitro,	   together	  with	   their	   distinct	   cell-­‐surface	   antigenic	   profile	   CD44+/CD24-­‐/low	   as	  well	   as	   high	  ALDH1	   expression.	   It	   has	   been	   suggested	   that	   BCSCs	   are	   responsible	   for	  therapeutic	  resistance,	  governing	  the	  metastatic	  process	  and	  tumor	  cell	  dormancy	  in	  the	  late	  stages	  of	  disease.	  	  We	  first	  evaluated	  ERβ	  protein	  expression	  with	  molecular	  subtypes	  in	  a	  cohort	  of	  187	   breast	   cancer	   patients	   with	   available	   gene	   expression-­‐based	   subclass	  categorization,	   and	   concluded	   ERβ	   expression	  was	   evenly	   distributed	   across	   all	  breast	   cancers.	   Dual	   immunohistochemical	   staining	   with	   ERβ	   and	   the	   BCSCs	  surface	   marker	   CD44	   was	   performed	   on	   the	   tissue	   microarray	   from	   the	   same	  cohort.	  Observed	  ERβ	  expression	  highly	  overlapped	  with	  CD44	  expression	  (71%).	  After	   successfully	   isolated	  BCSCs	   (mammospheres)	   from	  breast	   cancer	   biopsies,	  we	  performed	  immunofluorescent	  staining	  on	  another	  45	  patients,	  and	  confirmed	  that	   the	   vast	   majority	   of	   mammospheres	   were	   ERα-­‐	   ERβ+,	   CD44+/CD24-­‐,	   high	  ALDH1	   (>95%)	   and	   positive	   for	   PKH26,	   again	   showing	   that	   ERβ	   expression	   in	  BCSCs	  was	   independent	  of	  both	  tumor	  subtypes	  and	  ERα	  status.	  A	  similar	  result	  was	  also	  detected	  from	  mammary	  stem	  cells	  (MSCs).	  	  To	   further	   explore	   the	   mechanistic	   role	   of	   ERβ	   in	   BCSCs	   maintenance,	   we	  employed	   the	  MCF7	   (luminal-­‐like)	   and	  MDA-­‐MB-­‐231	   (basal-­‐like)	   cell	   lines,	   and	  generated	  spheres	  from	  these	  as	  surrogates	  for	  patient-­‐derived	  BCSCs.	  We	  could	  confirm	   these	   spheres	   were	   phenotypically	   similar	   to	   those	   of	   clinical	   ex	   vivo	  material	  by	  immunofluorescent	  staining.	  Reverse	  transcriptase-­‐polymerase	  chain	  reactions	  (RT-­‐PCR)	  showed	  that	  the	  cell	  line	  spheres	  were	  expressing	  high	  levels	  of	  ERβ	  along	  with	  the	  embryonic	  pluripotency	  genes	  SOX2,	  NANOG,	  OCT4.	  	  To	  assess	   the	   importance	  of	  ERβ	   for	  maintenance	  of	   the	  stem	  cell	   state,	  we	   first	  knocked	   out	   ERβ	   in	   the	   MCF7	   and	   MDA-­‐MB-­‐231	   spheres.	   Suppression	   of	   ERβ	  resulted	   in	   a	   significant	   reduction	   in	   mammosphere	   formation.	   In	   contrast,	  overexpression	  of	  exogenous	  ERβ	   increased	  the	  sphere-­‐forming	  capacity	   in	  each	  generation	  of	  cell	  culturing.	  Forced-­‐differentiation	  of	  clinical	  BCSCs	  reduced	  ERβ	  and	   ALDH1	   expression.	   We	   also	   performed	   proliferation	   and	   sphere	   formation	  assays.	  In	  cell	  line	  models,	  we	  found	  the	  ERβ-­‐selective	  agonist	  diarylpropionitrile	  (DPN)	  induced	  cell	  proliferation	  only	  in	  spheres	  but	  not	  in	  adherent	  cultures.	  This	  was	   confirmed	   in	   clinical	   BCSCs	   as	   well.	   More	   interestingly,	   treatment	   with	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tamoxifen,	   fulvestrant,	   or	   the	   ERα-­‐selective	   agonist	   propylpyrazoletrisphenol	  (PPT)	  did	  not	  cause	  any	  significant	  change	  in	  mammosphere	  formation	  in	  clinical	  BCSCs.	  When	   the	   same	   treatments	  were	  applied	   to	  MSCs,	   stimulation	  of	  ERβ	  by	  DPN	  caused	  a	  dramatic	  reduction	  in	  mammosphere	  formation.	  To	   further	   explore	   ERβ	   function	   in	   BCSCs,	   we	   performed	   whole-­‐transcriptome	  analysis	  of	  adherent	  MCF7	  and	  mammospheres	  (MCF7S)	  incubated	  with	  either	  a	  vehicle	  control	  or	  the	  agonist	  DPN.	  Transcriptomal	  changes	  after	  DPN	  treatment	  in	  MCF7	   and	   MCF7S	   revealed	   separate	   and	   distinct	   gene	   expression	   signatures.	  Gene-­‐set	   and	   pathway	   enrichment	   analysis	   found	   that	   the	   “HIF1α	   transcription	  factor	   network”	   and	   “genes	   involved	   in	   glucose	   metabolism”	   were	   the	   most	  significantly	  enriched	  pathways.	  Afterwards,	  clinical	  associations	  were	  performed	  using	  the	  signature	  generated	  from	  DPN-­‐stimulated	  MCF7S.	  We	  found	  high	  MCF7S	  DPN	  signature	  scores	  were	  statistically	  significantly	  associated	  with	  poor	  distant	  metastasis-­‐free	  survival	  in	  three	  independent	  breast	  cancer	  cohorts.	  To	  assess	   the	  effect	  on	   tumor-­‐initiating	  capacity	  of	  ERβ	   in	   vivo,	  we	   transplanted	  MCF7	   and	  MDA-­‐MB-­‐231	   cells	   in	   the	   form	   of	   spheres	   or	   adherent	   cultures	   into	  immune-­‐deficient	   xenografts	   according	   to	   the	   experimental	   purposes.	   We	  observed	   that	  when	  ERβ	  was	  suppressed	  either	  by	  an	   inhibitor	  4-­‐[2-­‐Phenyl-­‐5,7-­‐
bis(trifluoromethyl)pyrazolo[1,5-­‐a]pyrimidin-­‐3-­‐yl]phenol	   (PHTPP)	   or	   by	   knock-­‐out,	   the	   tumor	  volume	  was	  dramatically	  reduced	  whereas	  stimulation	  of	  ERβ	  by	  DPN	  gave	  rise	  to	  larger	  tumor	  growths.	  In	  compliance	  with	  previous	  results,	  when	  tumors	   were	   extracted	   and	   immunostained	   with	   different	   markers,	   we	   found	  PHTPP	   could	   either	   reduce	   the	   number	   of	   mitotic	   cells	   or	   decrease	   ALDH1	  positivity	   in	   the	   cells	   stimulated	  by	  E2.	  We	  also	   assessed	   the	   tumor	   suppressive	  role	   of	   PHTPP	   on	   clinical	   BCSCs.	   As	   expected,	   PHTPP	   completely	   abolished	   the	  stimulatory	  effect	  of	  E2	  on	  sphere	  formation.	  	  Finally,	  we	  investigated	  whether	  a	  combination	  of	  tamoxifen	  and	  PHTPP	  would	  be	  more	   efficient	   in	   blocking	   tumor	   growth.	   The	   results	   indicated	   that	   tamoxifen	  alone	  was	  not	  able	  to	  eliminate	  the	  tumor	  completely.	  Combining	  tamoxifen	  with	  PHTPP	  caused	  a	  gradual	  decrease	  in	  tumor	  size	  in	  response	  to	  increasing	  PHTPP	  dosage.	  In	  conclusion,	  ERβ	  is	  expressed	  evenly	  within	  all	  breast	  cancer	  subtypes	  and	  the	  expression	  of	  ERα	  is	  completely	  negative	  in	  cancer	  stem	  cells	  at	  the	  protein	  level,	  whereas	  it	  appears	  to	  be	  highly	  expressed	  in	  the	  majority	  of	  differentiated	  tumor	  cells.	   ERβ	   protein	   is	   expressed	   in	   the	   majority	   of	   cancer	   stem	   cells,	   and	   its	  expression	   declines	   as	   the	   cancer	   stem	   cells	   differentiate.	   Therefore,	   we	  hypothesized	  a	  shift	  from	  a	  high	  to	  a	  low	  ERα/ERβ-­‐ratio	  correlates	  with	  the	  tumor	  progression	  process.	  Our	  data	  from	  the	  proliferation	  and	  sphere	  formation	  assay	  illustrate	   ERβ	   as	   the	   predominant	   estrogen	   receptor	   that	   is	   essential	   for	   both	  normal	  and	  cancer	  stem	  cell	  phenotype	  maintenance.	  In	  vivo	  data	  suggest	  that	  ERβ	  inhibitors	  together	  with	  conventional	  endocrine	  therapy	  would	  be	  more	  efficient	  in	  targeting	  both	  the	  more	  differentiated	  (mainly	  ERα+/ERβ+)	  cells	  as	  well	  as	  the	  stem-­‐cell-­‐like,	  poorly	  differentiated	  cells	  (ERα-­‐/ERβ+).	  We	  thereby	  identify	  ERβ	  as	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a	  mediator	  of	  estrogen	  action	  and	  a	  novel	  target	  for	  endocrine	  therapy	  in	  BCSCs.	  
4.2 PAPER	  II	  
Sequencing	   of	   breast	   cancer	   stem	   cell	   populations	   indicates	   a	   dynamic	   conversion	  
between	  differentiation	  states	  in	  vivo	  Currently,	   two	  alternative	  and	  contradictive	  explanations	  have	  been	  proposed	  to	  describe	  the	  tumor	  progression	  process	  governed	  by	  CSCs	  in	  breast	  cancer	  (Figure	  4).	  In	  the	  first	  classical	  cancer	  stem	  cell	  model,	  a	  highly	  differentiated	  bulk	  tumor	  is	   generated	   as	   a	   consequence	  of	   proliferation	   and	   irreversible	   conversion	   from	  cancer	  stem	  cells.	  Therefore,	  an	  accumulation	  of	  unique	  mutations	  with	  low	  allelic	  frequencies	  should	  be	  observed	   in	   the	  rest	  of	   tumor.	   In	   the	  plasticity	  model,	   the	  cancer	  stem	  cell	  phenotype	  and	  the	  stochastic	  state	   in	  a	  bulk	  tumor	  maintain	  an	  equilibrium	  and	  a	  reversible	  transition	  through	  de-­‐differentiated	  modifications.	  In	  this	   model,	   mutations	   and	   allelic	   frequencies	   should	   display	   high	   similarities	  between	  these	  two	  compartments.	  	  
Figure	   4.	   Two	  main	   hypothesis	   of	   tumor	  progression	   by	  BCSCs.	   Stem-­‐like	   cells	   and	  differentiated	   epithelial	  tumor	  cells	  are	  labeled	  as	  different	  colors.	  (A)	  BCSCs	   irreversibly	  convert	   into	  other	  cells	  and	  undergo	  asymmetrical	  division	  to	  produce	  a	  hierarchical	  bulk	  tumor.	  (B)	  Plasticity	  and	  dynamic	  transition	  occasionally	  occur	  between	  BCSCs	  and	  differentiated	  tumor	  cells	  within	  a	  bulk	  tumor.	  
To	   investigate	   the	   hypotheses,	   we	   compared	   the	   spectra	   of	  mutational	   changes	  between	  breast	  cancer	  stem	  cell	  populations	  and	  the	  rest	  of	  the	  tumor	  cells	  from	  the	  same	  biopsy.	  The	  compartment	  of	  cancer	  stem	  cells	  were	  identified	  either	  by	  culture	  as	  mammospheres	  in	  vitro	  and	  characterized	  by	  a	  serious	  of	  experiments,	  or	  by	  direct	  cell	  isolation	  using	  fluorescent-­‐activated	  cell	  sorting	  (FACS)	  based	  on	  their	   surface	  marker	   profile	   CD44+/CD24-­‐,	   or	   high	   ALDH1.	  Mammospheres	   and	  biopsies	  were	  isolated	  from	  10	  patients	  and	  subjected	  to	  whole	  exome	  sequencing.	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Massive	   bioinformatics	   have	   been	   performed	   to	   detect	   the	   somatic	   mutational	  patterns	  within	   these	   two	  compartments	   from	  each	  patient.	  The	   investigation	  of	  the	   extent	   of	   shared	   mutations	   between	   BCSCs	   and	   primary	   bulk	   tumor	   found	  these	   to	   highly	   overlap.	   On	   average,	   83%	   of	   the	   mutations	   were	   shared.	   The	  difference	  between	  those	  shared	  mutations	  and	  the	  total	  number	  of	  mutations	  in	  bulk	   tumor	  was	   not	   statistically	   significant.	   Uni-­‐	   and	  multivariate	   analysis	   after	  adjustment	  for	  tumor	  characteristics	  still	  indicated	  no	  significant	  differences.	  The	  mutated	  allele	   frequency	  of	   the	  shared	  mutations	  was	  also	  evaluated,	  and	  it	  was	  shown	   to	   be	   similar	   between	   the	   BCSCs	   and	   bulk	   tumor	   as	   well.	   The	   same	  procedure	  was	  repeated	  on	  the	  mutations	  that	  were	  unique	  to	  each	  compartment,	  and	   the	   result	   showed	   the	   frequencies	   of	   unique	   mutations	   were	   significantly	  lower	  than	  the	  shared	  mutations.	  	  To	   validate	   the	   detected	   somatic	   mutations	   from	   exome	   sequencing	   analysis,	  ultra-­‐deep	  amplicon	  sequencing	  across	  selected	  14	  mutation	  sites	   (based	  on	   the	  mutational	  pattern)	  was	  performed	  on	  three	  patients.	  Using	  this	  method,	  only	  one	  mutation	  at	  a	  low	  allele	  frequency	  (5%)	  could	  be	  defined	  as	  BCSCs-­‐unique	  and	  the	  rest	  of	  the	  mutations	  were	  either	  shared	  or	  found	  to	  be	  false	  positive	  from	  the	  first	  round	  of	  analysis.	  	  Because	   there	   is	   some	  controversy	  about	  using	  mammospheres	   to	  define	  BCSCs	  populations,	   we	   also	   isolated	   two	   other	   subpopulations	   of	   BCSCs	   carrying	   the	  CD44+/CD24-­‐	  or	  high	  ALDH1	  profile	  by	  FACS	  sorting.	  After	  exome	  sequencing	  on	  these	  two	  subsets	  compared	  to	  their	  non-­‐CSCs	  component	  CD44-­‐	  or	   low	  ALDH1,	  respectively,	   the	   results	   again	   revealed	   the	   similarity	   of	   shared	   mutational	  patterns	  between	  BCSCs	  and	  non-­‐CSCs	  populations.	  Our	  data	  showed	  the	  somatic	  mutations	   in	   the	   BCSCs	   state	   and	   in	   the	   differentiated	   cell	   state	   were	   highly	  similar,	  as	  were	  the	  spreading	  allele	   frequencies	  over	   the	  spectrum.	  This	   finding	  was	  consistent	  across	  different	  methods	  to	  identify	  BCSCs	  populations.	  	  Our	   results	   support	   the	   plasticity	   model	   of	   BCSCs	   existence	   in	   the	   bulk	   tumor.	  First,	   we	   observe	   a	   high	   degree	   of	   shared	   mutations	   between	   BCSCs	   and	   the	  differentiated	   tumor	   cells,	   implying	   the	   occurrence	   of	   transition	   and	   inter-­‐conversion	  within	   these	   two	   cellular	   phenotypes.	   Hence,	   the	   dynamic	   cell	   state	  model	  is	  a	  better	  fit	  to	  the	  data.	  The	  large	  spread	  in	  allele	  frequencies	  seen	  in	  the	  two	   components	   also	  provides	   strong	   evidence	   that	   as	   early	  mutations	  occur	   in	  the	   rapidly	   dividing	   differentiated	   epithelial	   cells,	   the	   propagated	   offspring	   cells	  are	   occasionally	   reverting	   to	   stem-­‐cell-­‐like	   cancer	   cells,	   which	   harbor	   the	   same	  mutations.	  Since	   these	  early	  events	  are	  represented	  as	  high	  allele	   frequencies,	   it	  directly	  points	  out	  the	  fact	  that	  mutations	  accumulated	  in	  early	  tumorigenesis	  are	  able	   to	   be	   transmitted	   across	   all	   of	   the	   cell	   states	   during	   tumor	   progression;	  therefore,	   BCSCs	   can	   carry	   similar	   frequencies	   to	   those	   in	   the	   non-­‐tumorigenic	  cells.	  Although	   it	   has	  been	  noted	   that	   allele	   frequencies	   alone	  are	   inadequate	   to	  classify	  different	  subclones	  distinctively.	  In	  conclusion,	  we	  assume	  BCSCs	  as	  well	  as	   differentiated	   tumor	   cells	   exist	   in	   parallel	   in	   a	   bulk	   tumor	   rather	   than	   being	  distinct	  subsets	  of	  cells	  on	  the	  apex	  of	  a	  tumor	  progression	  hierarchy.	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4.3 PAPER	  III	  
mTOR	  inhibitors	  counteract	  tamoxifen-­‐induced	  activation	  of	  breast	  cancer	  stem	  cells	  In	   paper	   I,	   we	   noted	   that	   although	   tamoxifen	   could	   efficiently	   inhibit	   adherent	  cells	   from	   proliferating,	   such	   as	   the	   MCF7	   cell	   line,	   this	   effect	   appeared	   to	   be	  insufficient	  to	  reduce	  sphere	  formation	  from	  patient-­‐derived	  BCSCs.	  We	  decided	  to	  investigate	   the	   mechanism	   behind	   this	   intrinsic	   resistance	   to	   tamoxifen	   in	  mammosphere.	   Interestingly,	  we	   and	   others	   have	  proved	   that	  BCSCs	   are	   low	   in	  ERα	   and	   they	   appear	   not	   to	   be	   a	   distinct	   cancer	   cell	   lineage	   but	   are	   repeatedly	  created	   through	   dedifferentiation	   of	   bulk	   tumor	   cells.	   The	   comprehensive	  mechanism	  of	  tamoxifen	  resistance	  in	  ERα	  positive	  breast	  cancer	  has	  not	  yet	  been	  fully	   discovered,	   but	   the	   leading	   hypothesis	   involves	   cross-­‐reactivity	  with	   other	  growth	   factor	   signaling	   pathways	   or	   through	   imbalanced	   PI3K/AKT/mTOR	  signaling.	  These	   two	  possibilities	  have	  been	  suggested	   to	  be	  causes	   for	  acquired	  endocrine	   resistance	   in	   tumors	   retaining	   or	   gradually	   losing	   ERα.	   We	   were	  interested	  to	  understand	  whether	  the	  observed	  resistance	  in	  BCSCs	  had	  a	  similar	  mechanism,	   and	  whether	   the	  mechanism	   in	   ex	   vivo	   models	   could	   contribute	   to	  explaining	  the	  intrinsic	  tamoxifen	  resistance	  observed	  in	  patients	  with	  ER-­‐positive	  tumors.	  	  	  We	   isolated	   mammospheres	   from	   several	   patients	   and	   immuno-­‐stained	   with	  CD44,	   CD24,	   ALDH1,	   EpCAM,	   and	   other	   markers	   to	   characterize	   the	   BCSCs	  phenotype.	   We	   consistently	   observed	   that	   mammospheres,	   although	   a	   minor	  component	  in	  the	  bulk	  tumor,	  were	  enriched	  in	  the	  subset	  of	  cells	  carrying	  all	  of	  the	   required	   BCSCs	   properties.	   This	   finding	   was	   also	   observed	   in	   the	   cell-­‐line-­‐generated	  spheres.	  	  Patient-­‐derived	   and	   cell-­‐line	   models	   were	   treated	   with	   tamoxifen.	   Tamoxifen	  failed	   to	   prevent	   sphere	   formation	   in	   both	   patient-­‐derived	   BCSCs	   and	   cell	   line	  BCSCs,	   in	   contrast	   to	   its	   antagonizing	   effect	   on	   the	   adherent	   cultures.	  Mammospheres	   were	   purified	   from	   another	   seven	   breast	   cancer	   patients,	   and	  they	  were	   treated	  with	   tamoxifen	   or	  with	   the	   vehicle	   control.	   After	   performing	  whole	   transcriptome	   analysis,	   it	   was	   found	   that	   treatment	   with	   tamoxifen	  triggered	  a	  distinct	  gene	  expression	  pattern	  compared	  to	  the	  control.	  	  Gene-­‐set	  enrichment	  analyses	  were	  performed	  to	  explore	  the	  biological	  relevance	  of	  this	  differential	  expression	  pattern.	  The	  most	  significant	  pathways	  activated	  by	  tamoxifen	   in	   BCSCs	   were	   ribosome	   synthesis	   and	   mRNA	   translation.	   These	  indicated	  a	  highly	  activated	  mTOR-­‐signaling	  pathway	  enhanced	  by	  tamoxifen.	  We	  therefore	   selected	  well-­‐characterized	  downstream	  effectors	  of	  mTOR	   to	  validate	  the	   hypothesis.	   In	   western	   blotting	   results,	   two	   patient-­‐derived	   BCSCs	   cultures	  showed	   significant	   induction	   of	   phosphorylated	   S6RP	   by	   tamoxifen	   whereas	   in	  MCF7	   and	   T47D	   spheres,	   phosphorylated	   4E-­‐BP1	   was	   dramatically	   induced	   by	  tamoxifen.	  From	  immunofluorescent	  staining,	  phosphorylated	  S6RP	  induction	  can	  be	  detected	  in	  all	  of	  the	  cell	  cultures,	  although	  the	  self-­‐stimulation	  was	  higher	  in	  the	  cell	  lines	  and	  the	  level	  of	  induction	  varied	  among	  patients.	  Notably,	  all	  of	  these	  mTOR	  effectors,	  which	  were	  highly	  expressed	  in	  BCSCs	  after	  tamoxifen	  treatment,	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can	   be	   attenuate	   by	   a	   series	   of	  mTOR	   inhibitors.	   Again,	   when	  mTOR	   inhibitors	  were	   employed,	   either	   alone	   or	   in	   combination	   with	   tamoxifen,	   they	   could	  effectively	  reduce	  mammosphere	  formation.	  	  In	   conclusion,	   our	   data	   support	   the	   idea	   that	   tamoxifen	   may	   work	   as	   a	   partial	  agonist	  on	  BCSCs	  by	  activating	  this	  population	  and	  further	  driving	  relapsed	  tumor	  to	  become	  tamoxifen	  resistant.	  Based	  on	  the	  tamoxifen-­‐induced	  transcriptome	  in	  BCSCs	  and	  the	  proposed	  central	  role	  of	  mTOR	  governing	  endocrine	  resistance,	  we	  hypothesize	   that	   tamoxifen	   stimulates	   the	   mTOR	   pathway;	   thereby	   tamoxifen	  would	   increase	   the	   translational	  process	   for	  maintenance	  and	  viability	  of	  BCSCs.	  Of	   note,	   the	   mTOR	   signaling	   pathway	   is	   already	   active	   in	   BCSCs	   but	   is	   further	  stimulated	  by	   tamoxifen	   treatment,	   and	   this	   effect	   is	   independent	   of	   ERα	   status	  and	  can	  also	  be	  observed	  in	  triple-­‐negative	  patients.	  While	  antagonizing	  the	  mTOR	  activation	   by	  mTOR	   inhibitors,	  we	   noticed	   constitutive	   AKT	   activation	   that	  was	  not	   fully	   eliminated	   by	   rapa-­‐analogs.	   It	   should	   be	   taken	   into	   consideration	   that	  high	   levels	   of	   p-­‐AKT	   might	   reflect	   a	   mechanism	   of	   rapamycin	   resistance	   in	  paradoxical	   compensation	   initiated	   by	   mTOR	   inhibition.	   This	   is	   supported	   by	  previous	   studies	   reporting	   the	   problem	   with	   mTOR	   inhibition	   is	   the	   risk	   of	  blocking	  the	  negative	  feedback	  loop	  effect	  of	  insulin-­‐like	  growth	  factor-­‐1	  receptor	  (IGF-­‐1R)	  on	  AKT/PI3K	  signaling	  by	   increased	  AKT	  phosphorylation,	   and	   further	  abrogating	   the	   therapeutic	   effect.	   We	   report	   that	   a	   dual	   PI3K/mTOR	   kinase	  inhibitor,	   PF-­‐04691502,	   exhibited	   robust	   antitumor	   potent	   and	   exerts	   a	  preferential	  effect	  in	  targeting	  the	  BCSCs	  component.	  We	  suggest	  that	  a	  combined	  treatment	   of	   tamoxifen	   and	   rapalogs	   is	   a	  way	   to	   eradicate	   the	   CSCs	   population	  more	  efficiently	  in	  parallel	  with	  the	  bulk	  tumor.	  
4.4 PAPER	  IV	  
Superficial	   scrapings	   from	   breast	   tumors	   is	   a	   source	   for	   biobanking	   and	   research	  
purposes	  	  Nowadays,	  rapid	  evolving	  technologies	  such	  as	  next	  generation	  sequencing	  (NGS)	  pave	   the	   way	   forward	   to	   better	   diagnosis	   and	   therapy	   in	   breast	   cancer.	  Accordingly,	   clinical	   pathology	   laboratories	   would	   also	   expect	   to	   update	   their	  tissue-­‐handling	  pipelines	  to	  adapt	  to	  new	  demands	  for	  both	  scientific	  research	  and	  clinical	  uses.	  This	  requires	  guaranteed	  material	  quality,	  such	  as	  stable	  mRNA,	  DNA	  and	  protein,	  without	  compromising	  pathological	  diagnosis	  and	  the	  materials	  need	  to	   be	   representative	   compared	   to	   the	   original	   breast	   cancer	   specimen.	   Fresh-­‐frozen	  tissue	  is	  the	  ideal,	  and	  is	  the	  only	  way	  to	  preserve	  mRNA,	  DNA	  and	  protein	  efficiently	   for	   subsequent	   analysis.	   However,	   current	   guidelines	   for	   biobanking	  breast	   cancers	   requires	   tumor	   specimens	   to	   be	   at	   least	   1	   cm	   in	   diameter,	   and	  nearly	   25%	   of	   breast	   tumors	   are	   smaller	   than	   1	   cm.	   Since	   mammography	  screening	  dramatically	  increases	  the	  chances	  of	  discovering	  tumors	  at	  early	  stages,	  the	  percentage	  of	  small	  breast	  cancers	  will	  be	  expected	  to	  increase	  in	  the	  future.	  We	  have	  established	  a	  simple	  and	  standard	  method,	  using	  superficial	  scrapings,	  to	  biobank	   high-­‐quality	   samples	   from	   small	   tumors	   without	   disrupting	  histopathological	  examination.	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Since	   taking	   biopsies	   from	   breast	   cancers	   might	   introduce	   dilution	   and	  contamination	   by	   stromal	   cells	   or	   other	   cell	   types,	   we	   first	   assessed	   the	   cell	  component	   from	   superficial	   scraping	   in	   several	   patients.	   Cytological	   smear	  material	  was	  examined	  by	  a	  cytologist	  and	  revealed	  that	  the	  majority	  (>95%)	  of	  the	   scraping	   was	   composed	   of	   cancer	   cells.	   We	   also	   cultured	   the	   scrapings	   in	  selective	   cancer	   stem	   cell	   media	   and	   found	  mammosphere	   formation.	  With	   the	  previous	   knowledge	   of	   the	   mammosphere	   as	   a	   cancer	   stem	   cell	   enriched	  phenotype,	   we	   characterized	   those	   cells	   through	   a	   series	   of	   experiments	   and	  defined	   them	   as	   CD44+/CD24-­‐,	   high	   ALDH1,	   EpCAM+	   and	   PKH26+.	   We	   also	  generated	   adherent	   cancer	   cells	   by	   plating	   scrapings	   in	   the	   differentiating	   cell	  medium.	  	  To	  assess	  the	  sample	  quality,	  scrapings	  from	  tumors	  were	  directly	  transferred	  into	  cryopreservative	  tubes.	  The	  tubes	  were	  immediately	  put	  into	  liquid	  nitrogen	  and	  stored	   at	   -­‐80ºC.	   After	   1	   week,	   samples	   were	   thawed	   and	   DNA	   or	   mRNA	   was	  isolated.	  We	  also	  isolated	  mRNA	  from	  paired	  bulk	  tumor	  pieces	  as	  a	  comparison	  to	  assess	  mRNA	  recovery	  efficiency	  from	  the	  scrapings.	  After	  analysis	  on	  the	  basis	  of	  microchip	   gel	   electrophoresis	   and	   quantification	   by	   measuring	   the	   total	  absorbance,	   we	   observed	   distinct	   ribosomal	   peaks	   and	   a	   decent	   RNA	   integrity	  number	   (RIN)	   value	   from	   scrapings	   mRNA,	   indicating	   no	   severe	   degradation	  occurred	  during	  the	  biobanking	  procedure;	  also,	  the	  mRNA	  yields	  from	  scrapings	  were	   of	   acceptable	   purity,	   thereby	   enabling	   usage	   of	   scraping	  material	   for	   gene	  expression	  assays.	  	  To	   investigate	   whether	   the	   superficial	   scrapings	   can	   truly	   represent	   the	   gene	  expression	  pattern	  of	  the	  original	  breast	  cancers,	  we	  performed	  RT-­‐PCR	  on	  both	  scrapings	   and	   corresponding	   breast	   cancer	   biopsies.	   Results	   showed	   scrapings	  shared	   similar	   expression	  patterns	  of	  ERα	   and	  PR,	   but	  with	   a	   varied	   expression	  level	  compared	  to	  the	  parental	  tumor.	  They	  also	  expressed	  much	  lower	   levels	  of	  fibroblastic	  markers	   (PDGFRβ,	  α-­‐SMA)	  and	  higher	   levels	  of	   the	  epithelial	  marker	  
EpCAM.	   This	   reflected	   the	   enriched	   fraction	   of	   cancer	   cells	   in	   the	   superficial	  scrapings.	  Scraping	   DNA	   quality	   assessment	   was	   also	   performed.	   The	   results	   indicated	  proper	   DNA	   yields,	   and	   sufficient	   purity	   and	   integrity	   for	   next	   generation	  sequencing	  after	  low	  temperature	  storage.	  Additionally,	  we	  investigated	  the	  usage	  of	  scraping	  material	  for	  epigenetic	  studies.	  Scraping	  DNA	  extracted	  from	  two	  ERα	  positive	   patients	   was	   used	   to	   analyze	   the	   ERα	   methylation	   status	   using	   the	  pyrosequencing	   technique.	   Analysis	   indicated	   the	   scrapings	   retained	   the	   key	  methylation	  signatures,	  which	  correlated	  to	  the	  gene	  expression	  of	  the	  bulk	  tumor	  itself.	  	  The	  conducted	  validations	  on	  the	  scrapings	  from	  dissected	  tumor	  surface	  strongly	  suggest	  they	  could	  be	  successfully	  used	  for	   investigations	  at	  the	  DNA	  and	  mRNA	  level.	  Apart	   from	   their	  use	   for	   gene	   expression	  and	  next	   generation	   sequencing,	  these	  materials	   are	   also	   valuable	   for	   cancer	   stem	   cell	   research	   and	  methylation	  studies,	   since	   accumulating	   reports	   show	   the	   importance	   of	   considering	   cancer	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stem	  cells	  for	  potential	  relapse,	  metastasis	  and	  treatment	  resistance.	  Studies	  at	  the	  epigenetic	   level	   appear	   to	   be	   promising	   methods	   for	   therapeutic	   response	  prediction.	  However,	  we	  could	  not	  use	  this	  material	  from	  small	  tumors	  for	  current	  proteomics	  investigations	  since	  the	  input	  amount	  is	  required	  to	  be	  in	  the	  20-­‐50	  µg	  ranges.	   Currently,	   at	   the	   Department	   of	   Pathology	   in	   Karolinska	   University	  Hospital,	   the	   routine	   biobank	   procedure	   through	   standard	   biopsies	   taken	   from	  fresh	  tumor	  tissue	  includes	  approximately	  60%	  of	  all	  cancers.	  By	  using	  this	  simple	  and	  robust	  technique	  using	  scrapings,	  we	  could	  also	  collect	  fresh	  cells	  from	  small	  tumors	   and	   further	   increase	   the	   biobank	   inclusion	   of	   up	   to	   85%	  of	   all	   resected	  tumors.	  In	  summary,	  we	  conclude	  superficial	  scrapings	  are	  as	  an	  effective	  source	  for	  both	  biobanking	  and	  research	  purposes.	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5 FUTURE	  PERSPECTIVES	  
Breast	  cancer	  stem	  cells	  -­‐	  myths	  or	  facts?	  The	  concept	  of	  breast	   cancer	  stem	  cells	  has	  been	  established	  over	  decades.	  However,	  none	  of	  the	  reports	  ever	  precisely	  defined	  the	  real	  cancer	  stem	  cells	  in	  a	  bulk	  tumor.	  All	  of	  the	  conclusions	  up-­‐to-­‐date	  are	  merely	  based	  on	  cell	  surface	  antigen	  profiles	  or	  certain	  patterns	  of	  protein	  expression	  status	  to	  isolate	  a	  subset	  of	  cellular	  components	  within	  solid	  tumors.	  Their	  existence	  can	  only	  be	  indirectly	  proved	  as	  only	  a	  few	  isolated	  cells	  subjected	  to	  xenograft	  ever	  give	  rise	  to	  an	  integrated	  tumor.	  	  As	   discussed	   previously,	   several	   groups	   have	   evaluated	   genotypes	   and	   biological	  functions	  of	  BCSCs	  purified	  using	  different	   isolating	  methods	  or	  different	   subtypes	  of	  breast	   cancer.	  There	   are	   several	   key	   findings:	   1.	  BCSCs	   isolated	  by	  different	  methods	  display	  different	   lineages	  during	   cancer	  progression;	   2.	   BCSCs	   isolated	   from	  different	  subtypes	  of	  tumors	  harbor	  inter-­‐tumor	  heterogeneity;	  3.	  Not	  all	  of	  the	  BCSCs	  generated	  from	  a	  certain	  subtype	  of	  breast	  cancer	  can	  successfully	  reform	  a	  parental-­‐tumor-­‐like	  secondary	  tumor	  in	  the	  xenografts.	  Therefore,	  BCSCs	  seem	  to	  be	  a	  distinct	  small	  group	  of	  cells	  only	  within	  an	  individual	  tumor.	  In	  addition,	  the	  theory	  of	  BCSCs	  fails	  to	  explain	  how	   breast	   cancer	   initiates	   and	   progresses	   to	   develop	   inter-­‐	   and	   intra-­‐	   tumor	  heterogeneity	  during	  the	  later	  stages.	  	  This	  heterogeneity	  is	  an	  interesting	  issue	  in	  breast	  cancer	  evolution,	  once	  revealed,	  at	  least	  it	  can	  serve	  as	  a	  more	  precise	  prognosticator	  to	  define	  patients	  under	  high	  risk	  of	  breast	   cancer	   occurrence	   at	   certain	   ages.	  We	   and	   others	   have	   reported	   that	   current	  BCSCs	  are	  only	  a	  phenotype	  that	  occasionally	  dedifferentiates	  and	  re-­‐forms	  from	  other	  differentiated	  epithelial	  cancer	  cells.	  Hence,	  as	  currently	  defined,	  BCSCs	  are	  insufficient	  to	   fully	   explain	   breast	   cancer	   initiation	   and	   cannot	   be	   utilized	   for	   predicting	   breast	  cancer	  occurrence.	  	  However,	  in	  my	  personal	  opinion,	  the	  importance	  of	  recognizing	  current	  BCSCs	  isolated	  by	  different	  methods	  matters	  more	  in	  how	  they	  influence	  therapeutic	  outcomes.	  First,	  it	  has	   to	   be	   emphasized	   here	   that	   the	   present	   conception	   of	   BCSCs	   should	   be	   better	  understood	   as	   a	   niche	   where	   several	   cell	   components	   coordinating	   together	   act	   on	  similar	  stem-­‐cell-­‐like	  behaviors.	  In	  vitro	  studies	  showed	  BCSCs	  characterized	  from	  both	  breast	   cancer	   patient	  material	   and	   different	   cell	   lines	   all	   exhibit	   unique	   responses	   to	  conventional	  therapies	  (tamoxifen,	  chemo-­‐,	  radio-­‐	  therapy)	  compare	  to	  other	  cells	  from	  the	   same	   source.	   However,	   they	   are	   able	   to	   form	   an	   integrated	   tumor	   display	   with	  molecular	  profiling	  similar	  to	  the	  original	   tumor	  when	  subject	  to	  xenografts,	  although	  the	  tumor	  take-­‐out	  ratio	  is	  quite	  low.	  	  Taken	   into	   consideration	   all	   of	   facts	   discussed	   above,	   it	   is	   possible	   to	   conclude	   the	  following:	  1.	  Currently-­‐defined	  BCSCs	  perform	  their	  therapeutic	  resistance	  function	  not	  as	  consequence	  of	  a	  single	  cell	  or	  real	  cancer	  stem	  cells,	  it	  through	  the	  cooperation	  with	  other	  cells	  in	  the	  same	  niche	  and	  further	  facilitated	  by	  surrounding	  tumor	  cells.	  2.	  Long-­‐term	  conventional	  therapies	  can	  increase	  the	  occasions	  that	  force	  cancer	  epithelial	  cell	  dedifferentiation	   to	   form	  more	   BCSCs.	   3.	   Induced	   an	   increased	   number	   of	   BCSCs	   or	  already	   existed	   BCSCs	   surviving	   from	   conventional	   therapies	   can	   lead	   to	   further	  resistance	   to	   various	   therapies.	   4.	   As	   long	   as	   they	   survive,	   BCSCs	   can	   reconstruct	   a	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second	  tumor	  in	  the	  form	  of	  local	  relapse	  or	  distant	  metastasis,	  although	  the	  chance	  of	  this	  happening	  might	  be	   low.	  Therefore,	  studies	   focusing	  on	  BCSCs	  peculiar	  biological	  features	   and	   functions	   are	   highly	   encouraged.	   Administrating	   treatments	   to	   target	  BCSCs	   specifically	   seems	   to	  be	   inferior	   to	  a	   combination	  of	   treatments	   targeting	  both	  compartments.	   A	   novel	   therapeutic	   strategy	   should	   be	   established	   for	   treating	  differentiated	  cancer	  cells	  in	  parallel	  with	  eliminating	  BCSCs	  more	  efficiently.	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  my	  cousin,	  we	  talked	  about	  everything	  to	  each	  other!	  Good	  luck	  with	  your	  projects	  in	  Linkoping!	  Xiaonan	  and	  Fan:	  So	  sweet	  to	  see	  your	  couple!	  Xiaonan	  I	  really	  appreciate	  our	  friendship	  and	  thank	  you	  for	  being	  around	  during	  my	  PhD!	  Limin:	  You	  smile	  is	  so	  attractive!	  Thank	  you	  for	  giving	  it	  to	  me!	  	  Lidi	  and	  Peng:	  I	  got	  a	  lot	  of	  help	  from	  you!	  Hope	  your	  family	  will	  be	  full	  of	  happiness!	  	  
Mao	  and	  Nina:	  Smart	  guy	  with	  a	  kind	  girl!	  Thank	  you	  for	  all	  the	  discussion	  we	  had!	  
Yuan,	  Mei,	  Qiang,	  Peng,	  Na,	  Yuanjun:	  I	  would	  always	  feel	  supported	  from	  you,	  thank	  you	  all!	  
My	  friends	  outside	  CCK	  
Hao	  and	  Dan:	  When	  we	  are	  so	  close	  to	  each	  other,	  words	  are	  not	  enough	  to	  describe	  my	  appreciation!	  I	  am	  so	  glad	  to	  have	  and	  enjoy	  your	  company	  during	  these	  years,	  we	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are	  forever	  friends!	  Bo	  and	  Jiao:	  I	  wish	  your	  new	  family	  member	  will	  bring	  many	  happiness!	  	  Dr	  Zhu	  and	  Yunle:	  I	  always	  had	  great	  time	  with	  you!	  Thank	  you	  for	  sharing	  so	  many	  good	  things	  with	  me,	  great	  dinner,	  game	  night,	  picnic	  on	  the	  island.	  We	  will	  enjoy	  more	  later!	  Qinzi	  and	  Shuo:	  When	  I	  just	  came	  to	  Stockholm	  along,	  you	  are	  one	  of	  my	  first	  friends	  I	  made!	  Thank	  you	  for	  giving	  me	  good	  time!	  Best	  wishes	  to	  your	  family!	  
Ning:	  You	  are	  always	  energetic,	  amazing!	  We	  had	  great	  fun	  many	  times.	  Thank	  you!	  
Anqi,	  Ruiqing:	  My	  old	  friends	  since	  Uppsala	  time	  J	  Thank	  you	  for	  your	  friendship!	  	  
Tim,	  Clare	  and	  Vincent,	  Kayoko,	  Pegah,	  Hongya	  and	  Xinyan,	  Linjing	  and	  
Zhangshen,	  Ting	  and	  Jian,	  Rui,	  Shanshan,	  Yao,	  Yixin,	  Jianren	  and	  Na,	  Xintong,	  
Xinming,	  Yabin,	  Junwei	  and	  Daohua,	  Heng,	  Shaobo:	  I	  am	  so	  lucky	  to	  get	  to	  know	  you	  all!	  Thank	  you	  for	  being	  so	  kind	  and	  helpful.	  	  
Biobank	  and	  all	  the	  pathologists	  
Greg,	  Johan,	  Lud,	  Jonas	  and	  all	  biobank	  team:	  Thank	  you	  very	  much	  for	  your	  patience	  and	  help!	  You	  contribute	  a	  lot	  in	  helping	  me	  with	  this	  thesis!	  Lori,	  Felix,	  
Christofer	  and	  all	  the	  pathologists:	  Thank	  you	  for	  working	  extra	  to	  take	  good	  samples	  for	  us	  and	  for	  research!	  I	  appreciate	  a	  lot!	  	  
Xuan:	  My	  best	  friend!	  We’ve	  been	  friends	  since	  high	  school.	  In	  these	  years,	  I	  could	  always	  have	  your	  cares	  and	  supports	  around,	  and	  you	  never	  ask	  them	  back	  from	  me!	  I	  really	  think	  I	  am	  spoiled	  by	  your	  friendship,	  and	  I	  feel	  so	  blessed	  to	  have	  it!	  We	  are	  best	  friends	  to	  each	  other	  no	  matter	  where	  we	  are!	  	  	  	  








Xinsong	  I	  find	  it	  difficult	  to	  express	  my	  appreciation	  to	  you	  because	  it	  is	  so	  boundless.	  You	  are	  my	  most	  enthusiastic	  cheerleader;	  my	  best	  friend;	  and	  an	  amazing	  company	  in	  life.	  Without	  your	  sunny	  optimism,	  I	  would	  be	  a	  grumpy	  person;	  without	  your	  support,	  I	  would	  be	  lost.	  I	  am	  grateful	  to	  you	  not	  just	  because	  you	  are	  so	  dedicative	  to	  me	  and	  always	  prioritize	  my	  things	  in	  our	  lives,	  but	  also	  you	  have	  seen	  me	  through	  the	  ups	  and	  downs	  of	  the	  entire	  PhD	  process.	  I	  am	  happy	  that	  it	  is	  you	  shared	  this	  entire	  amazing	  journey	  with	  me!	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